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A B S T R A C T
Background
Occupational exposure to hazardous drugs can decrease fertility and result in miscarriages, stillbirths, and cancers in healthcare staff.
Several recommended practices aim to reduce this exposure, including protective clothing, gloves, and biological safety cabinets (’safe
handling’). There is significant uncertainty as to whether using closed-system drug-transfer devices (CSTD) in addition to safe handling
decreases the contamination and risk of staff exposure to infusional hazardous drugs compared to safe handling alone.
Objectives
To assess the effects of closed-system drug-transfer of infusional hazardous drugs plus safe handling versus safe handling alone for
reducing staff exposure to infusional hazardous drugs and risk of staff contamination.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, OSH-UPDATE, CINAHL,
Science Citation Index Expanded, economic evaluation databases, theWorld HealthOrganization International Clinical Trials Registry
Platform, and ClinicalTrials.gov to October 2017.
Selection criteria
We included comparative studies of any study design (irrespective of language, blinding, or publication status) that compared CSTD
plus safe handling versus safe handling alone for infusional hazardous drugs.
Data collection and analysis
Two review authors independently identified trials and extracted data. We calculated the risk ratio (RR) and mean difference (MD)
with 95% confidence intervals (CI) using both fixed-effect and random-effects models. We assessed risk of bias according to the risk of
bias in non-randomised studies of interventions (ROBINS-I) tool, used an intracluster correlation coefficient of 0.10, and we assessed
the quality of the evidence using GRADE.
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Main results
We included 23 observational cluster studies (358 hospitals) in this review. We did not find any randomised controlled trials or formal
economic evaluations. In 21 studies, the people who used the intervention (CSTD plus safe handling) and control (safe handling alone)
were pharmacists or pharmacy technicians; in the other two studies, the people who used the intervention and control were nurses,
pharmacists, or pharmacy technicians. The CSTD used in the studies were PhaSeal (13 studies), Tevadaptor (1 study), SpikeSwan (1
study), PhaSeal and Tevadaptor (1 study), varied (5 studies), and not stated (2 studies). The studies’ descriptions of the control groups
were varied. Twenty-one studies provide data on one or more outcomes for this systematic review. All the studies are at serious risk of
bias. The quality of evidence is very low for all the outcomes.
There is no evidence of differences in the proportion of people with positive urine tests for exposure between the CSTD and control
groups for cyclophosphamide alone (RR 0.83, 95% CI 0.46 to 1.52; I² = 12%; 2 studies; 2 hospitals; 20 participants; CSTD: 76.1%
versus control: 91.7%); cyclophosphamide or ifosfamide (RR 0.09, 95% CI 0.00 to 2.79; 1 study; 1 hospital; 14 participants; CSTD:
6.4% versus control: 71.4%); and cyclophosphamide, ifosfamide, or gemcitabine (RR not estimable; 1 study; 1 hospital; 36 participants;
0% in both groups).
There is no evidence of a difference in the proportion of surface samples contaminated in the pharmacy areas or patient-care areas for
any of the drugs except 5-fluorouracil, which was lower in the CSTD group than in the control (RR 0.65, 95% CI 0.43 to 0.97; 3
studies, 106 hospitals, 1008 samples; CSTD: 9% versus control: 13.9%).
The amount of cyclophosphamide was lower in pharmacy areas in the CSTD group than in the control group (MD −49.34 pg/cm²,
95% CI −84.11 to −14.56, I² = 0%, 7 studies; 282 hospitals, 1793 surface samples). Additionally, one interrupted time-series study
(3 hospitals; 342 samples) demonstrated a change in the slope between pre-CSTD and CSTD (3.9439 pg/cm², 95% CI 1.2303 to
6.6576; P = 0.010), but not between CSTD and post-CSTD withdrawal (−1.9331 pg/cm², 95% CI −5.1260 to 1.2598; P = 0.20).
There is no evidence of difference in the amount of the other drugs between CSTD and control groups in the pharmacy areas or
patient-care areas.
None of the studies report on atmospheric contamination, blood tests, or other measures of exposure to infusional hazardous drugs
such as urine mutagenicity, chromosomal aberrations, sister chromatid exchanges, or micronuclei induction.
None of the studies report short-term health benefits such as reduction in skin rashes, medium-term reproductive health benefits such
as fertility and parity, or long-term health benefits related to the development of any type of cancer or adverse events.
Five studies (six hospitals) report the potential cost savings through the use of CSTD. The studies used different methods of calculating
the costs, and the results were not reported in a format that could be pooled via meta-analysis. There is significant variability between
the studies in terms of whether CSTD resulted in cost savings (the point estimates of the average potential cost savings ranged from
(2017) USD −642,656 to (2017) USD 221,818).
Authors’ conclusions
There is currently no evidence to support or refute the routine use of closed-system drug transfer devices in addition to safe handling
of infusional hazardous drugs, as there is no evidence of differences in exposure or financial benefits between CSTD plus safe handling
versus safe handling alone (very low-quality evidence). None of the studies report health benefits.
Well-designed multicentre randomised controlled trials may be feasible depending upon the proportion of people with exposure. The
next best study design is interrupted time-series. This design is likely to provide a better estimate than uncontrolled before-after studies
or cross-sectional studies. Future studies may involve other alternate ways of reducing exposure in addition to safe handling as one
intervention group in a multi-arm parallel design or factorial design trial. Future studies should have designs that decrease the risk of
bias and enable measurement of direct health benefits in addition to exposure. Studies using exposure should be tested for a relevant
selection of hazardous drugs used in the hospital to provide an estimate of the exposure and health benefits of using CSTD. Steps should
be undertaken to ensure that there are no other differences between CSTD and control groups, so that one can obtain a reasonable
estimate of the health benefits of using CSTD.
P L A I N L A N G U A G E S U M M A R Y
Closed-system drug-transfer devices for reducing exposure to infusional hazardous medicines in healthcare staff
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Somemedicines - whether given as tablets or as a drip through the veins - are hazardous to the healthcare staff who handle them. Patients
receive infusional hazardous medicines through the veins as treatment for serious diseases like cancer. When healthcare staff are exposed
to these medicines, they can decrease their fertility and result in miscarriages, stillbirths, and cancers. Several recommended practices
can reduce healthcare staff exposure to these hazardous medicines. These include protective clothing, gloves, and special cabinets where
staff can prepare the hazardous medicines prior to giving them to patients. Together, these practices constitute ’safe handling’. A closed-
system drug-transfer device (CSTD) is a device system that mechanically prevents the escape of hazardous drug outside the system.
What is the aim of this review?
There is significant uncertainty as to whether using CSTD in addition to safe handling decreases the exposure and risk of staff
contamination to hazardous medicines compared to safe handling alone. We sought to resolve this issue by searching for existing studies
on the topic.
Key messages
Based on very low-quality evidence, there is currently no evidence for or against adding CSTD to safe handling of hazardous medicines.
Further well designed studies are necessary.
What was studied in the review?
We included all types of studies that compared CSTD plus safe handling (’CSTD group’) and safe handling alone (’control group’).
What are the main results of the review?
We included 23 studies (358 hospitals) in this review, none of which used the gold standard study design (randomised controlled
trials) or explored a treatment’s value for money. In 21 studies, the people who used the CSTD and safe handling were pharmacists or
pharmacy technicians. Nineteen studies provide information that could be included for this study.
There is no evidence of any benefit for using CSTD in the indirect measures of exposure such as the presence of the hazardous drug
in the urine of the healthcare professionals. There is no evidence that the contamination of surfaces or the floor with most hazardous
medicines was decreased by the use of CSTD. There is significant variability between the studies in terms of whether the use of CSTD
resulted in cost savings, with some studies reporting increased costs and others reporting decreased costs after introducing CSTD. None
of the studies report on health benefits such as reduction in skin rashes, infertility, miscarriage, development of any type of cancer, or
adverse events.
The overall quality of evidence is very low for all the outcomes because all the studies had one or more significant limitation in their
design. Therefore, the results may not be reliable.
How up-to-date is this review?
We searched for studies up until 26 October 2017.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Closed-system transfer device safe handling versus safe handling alone for reducing healthcare staff exposure to infusional hazardous drugs: exposure and contamination
Patient or population: healthcare staf f who handle infusional hazardous drugs
Settings: hospitals
Intervention: closed-system transfer device plus safe handling
Control: safe handling alone




Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Safe handling alone Closed-system transfer de-
vice plus safe handling
Exposure (urine tests for exposure)




















There were no part icipants with exposure in either group. 4 hospitals
(36 part icipants; 1 study)
⊕©©©
Very lowa,b,c
Other measures of expo-
sure
None of the studies report on blood tests or other measures of exposure to infusional hazardous drugs such as urine mutagenicity, chromosomal
aberrat ions, sister chromatid exchanges, or m icronuclei induct ion
Surface contamination (proportion of surfaces contaminated)
Pharmacy areas

















































































































































































(2332 samples; 9 studies)
⊕©©©
Very lowa,b,d





(1781 samples; 6 studies)
⊕©©©
Very lowa,b,d





(1008 samples; 3 studies)
⊕©©©
Very lowa,d,f





(780 samples; 2 studies)
⊕©©©
Very lowa,b,d











There is no evidence of dif f erence in the proport ion of samples contaminated with
5-f luorouracil, cytarabine, gemcitabine, irinotecan, docetaxel, paclitaxel, vinorelbine,
ganciclovir, or mult iple drugs in pharmacy areas between closed-system transfer
device plus safe handling versus safe handling alone
Irinotecan, docetaxel, pacli-
taxel, vinorelbine: 83 hospi-
tals
(493 samples; 1 study)
Ganciclovir: 1 hospital
(287 samples; 1 study)
Mult iple drugs: 4 hospitals









(1535 samples; 5 studies)
⊕©©©
Very lowa,b,d





(1535 samples; 5 studies)
⊕©©©
Very lowa,b,d

















































































































































































There is no evidence of dif f erence in the proport ion of samples contaminated with
5-f luorouracil, cytarabine, gemcitabine, irinotecan, docetaxel, paclitaxel, vinorelbine,
mult iple drugs in pat ient-care areas between closed-system transfer device plus safe





(493 samples; 1 study)
Mult iple drugs: 4 hospitals
(33 samples; 1 study)
⊕©©©
Very lowa,b,d
Surface contamination (quantity of surface contamination (pg/cm²))
Pharmacy areas
Cyclophosphamide‡ The mean cyclophospha-
mide in the control group is
124.30 pg/cm²
The mean cyclophospha-
mide in the intervent ion
group is 49.34 pg/cm²
lower




(1793 samples; 7 studies)
⊕©©©
Very lowa,b,f
Ifosfamide The mean ifosfamide in the
control group is
10.8 pg/cm²
The mean ifosfamide in the
intervent ion group is 0.32
pg/cm² lower




(1749 samples; 6 studies)
⊕©©©
Very lowa,b,d
Methotrexate The mean methotrexate in
the control groups is
18.23 pg/cm²
The mean methotrexate in
the intervent ion group is 3.
09 pg/cm² lower




(1749 samples; 6 studies)
⊕©©©
Very lowa,b,d
5-fluorouracil The mean 5-f luorouracil in
the control groups is
8720.5 pg/ cm²
The mean 5-f luorouracil in
the intervent ion group is
257.87 pg/cm² higher (459.









There is no evidence of dif f erence in the amount of cytarabine, gemcitabine, and
irinotecan in pharmacy areas between closed-system transfer device plus safe handling
and safe handling alone
83 hospitals








































































































































































Cyclophosphamide The mean cyclophospha-




mide in the intervent ion
group is
13.34 pg/cm² lower




(1535 samples; 5 studies)
⊕©©©
Very lowa,b,d,e
Ifosfamide The mean ifosfamide in the
control group is
4.59 pg/cm²
The mean ifosfamide in the
intervent ion group is
3.59 pg/cm² higher




(1535 samples; 5 studies)
⊕©©©
Very lowa,b,d
Methotrexate The mean methotrexate in
the control groups is
1.42 pg/cm²
The mean methotrexate in
the intervent ion group is 0.
10 pg/cm² higher









There is no evidence of dif f erence in the amount of 5-f luorouracil, cytarabine, gem-
citabine, and irinotecan in pat ient-care areas between closed-system transfer device
plus safe handling and safe handling alone
83 hospitals
(460 samples; 1 study)
⊕©©©
Very lowa,b,d
Other measures of contam-
ination
None of the studies report on atmospheric contaminat ion.
CI: conf idence interval; MD: mean dif ference; RR: risk rat io
* The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
Report contains mult iple drugs with no outcome information on individual drugs.
‡In addit ion, one interrupted t ime-series study (three hospitals; 342 samples) provided data on the quant ity of contaminat ion with cyclophosphamide f rom surface samples
in pharmacy areas during three phases, init ial phase of no CSTD, followed by CSTD, and then by no CSTD, each phase last ing three weeks (Harrison 2006). The authors took
biweekly measurements in all three phases. Between the f irst two phases, the change in the slope between pre-CSTD and CSTD was 3.9439 pg/ cm² (95%CI 1.2303 to 6.6576;
P = 0.01). Between the second and third phases, the slope and level were expected to rise again but the change in the slope between CSTD and post-CSTD withdrawal was





































































































































































GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
aThe study or studies was or were at serious risk of bias (downgraded one level for risk of bias).
bThe conf idence intervals were wide (downgraded one level for imprecision).
cThe sample size was small (downgraded one level for imprecision).
dThis is a surrogate measure of health benef it (downgraded one level for indirectness).
eThere was possible evidence of publicat ion bias (Egger’s test P value < 0.05) (downgraded one level for publicat ion bias).
f There is no evidence that this small dif f erence in levels of cyclophosphamide leads to decreased exposure or tangible health





































































































































































B A C K G R O U N D
Description of the condition
Hazardous drugs include those used for cancer chemotherapy,
antiviral drugs, hormones, some bioengineered drugs, and other
drugs (NIOSH2004). Although there is some variation in the defi-
nition of hazardous drugs, theNational Institute forOccupational
Safety and Health (NIOSH) describes hazardous drugs as those
that have the potential to cause one or more of the following: car-
cinogenicity (inducing cancer), teratogenicity (causing birth de-
fects), developmental toxicity (having an adverse impact on devel-
opment), reproductive toxicity (interfering with normal reproduc-
tion), organ toxicity at low doses (damaging organs), or genotox-
icity (causing mutations, i.e. alterations in the genetic structure)
(NIOSH 2004). New drugs that have a structure and toxicity pro-
file that mimics existing drugs considered hazardous according to
the above criteria are also considered hazardous (NIOSH 2004).
There is a subtle difference between cytotoxic drugs and hazardous
drugs. Cytotoxic drugs are medicines that are toxic to human cells
(NCBI 1978), while hazardous drugs include cytotoxic drugs and
new drugs that have a structure and toxicity profile similar to cy-
totoxic drugs.
The various types of hazardous drugs include alkylating drugs (e.g.
cyclophosphamide, chlorambucil), anthracyclines and other cy-
totoxic antibiotics (e.g. daunorubicin, doxorubicin), antimetabo-
lites (e.g. methotrexate, fluorouracil, gemcitabine), vinca alkaloids
and etoposide (e.g. vinblastine, vincristine), and some antineoplas-
tic drugs (e.g. bevacizumab, denosumab, pertuzumab, rituximab,
trastuzumab, mitotane) (BNF 2017). The mechanism of action
varies between different types of cytotoxic drugs. In general, cy-
totoxic drugs interfere with cell replication by damaging DNA or
by preventing normal cell division (BNF 2017).
Cytotoxic drugs have anticancer activity and immunosuppres-
sive properties (Brogan 2000). Therefore, they are used in the
treatment of many cancers (e.g. breast cancer, bowel cancer,
stomach cancer, sarcoma, leukaemia) and non-cancerous condi-
tions that require immunosuppression (e.g. polyarteritis nodosa,
Wegener’s granulomatosis, systemic lupus erythematosus, idio-
pathic nephrotic syndrome, inflammatory bowel disease, mixed
connective tissue disease, scleroderma, multiple sclerosis, idio-
pathic inflammatory myopathy, sarcoidosis, primary membra-
nous nephropathy, membranoproliferative glomerulonephritis,
transplantation) (Awad 2009; BNF 2017; Brogan 2000; Cassidy
2011; Fernandes Moca Trevisani 2013; Ge 2015; Hartman 2001;
Hazlewood 2016;Mulder 2015;Nunes 2015; Poormoghim 2012;
Rodriguez-Peralvarez 2017; Zhu 2017).
Hazardous drugs can be administered orally, intravenously by
infusions, or intrathecally (BNF 2017). When hazardous drugs
are given by intravenous infusion, there is a risk of contamina-
tion, which means that staff handling the infusional hazardous
drugs, particularly the pharmacy technicians who prepare the
drugs and the nurses who administer them, may come into con-
tact with them. The hazardous drug aerosol, formed due to the
spillage of drugs during preparation, transport, or administration,
can be inhaled or absorbed through the skin (Chu 2012; Hon
2014; Poupeau 2016; Ramphal 2014; Schierl 2016; Sessink 2011;
Sessink 2015; Sugiura 2011; Viegas 2014; Yoshida 2011; Yoshida
2013). Other staff (e.g. pharmacists, respiratory therapists, physi-
cians, support staff ) working in the hospital that administers haz-
ardous drugs can also be exposed to the contamination, not just
those who handle the hazardous drugs) (Hon 2014; Ramphal
2014).
Occupational exposure to hazardous drugs increases mutations
that predispose the exposed staff to the development of cancer
(HSE 2017; Mahmoodi 2017; McDiarmid 2010; McDiarmid
2014; Moretti 2015; NIOSH 2004; Skov 1992). Maternal occu-
pational exposure to hazardous drugs during pregnancy can cause
congenital abnormalities, miscarriages, stillbirths, and low birth-
weight (Connor 2014; HSE 2017; NIOSH 2004). Occupational
exposure to hazardous drugs can also decrease fertility in women
(Connor 2014; HSE 2017; NIOSH 2004). Other adverse ef-
fects include skin rash, hair loss, light-headedness, abnormal blood
counts, liver damage, abdominal pain, and vomiting (HSE 2017;
NIOSH 2004).
Several methods have been proposed to decrease the risk of ex-
posure to hazardous drugs. These include the use of biological
safety cabinets with laminar airflow for drug preparation, robotic
drug preparation, centralisation of priming of intravenous tub-
ing, personal protective equipment, staff education for safe han-
dling of hazardous drugs, and closed-system drug transfer devices
(Guillemette 2014; Schierl 2016; Sessink 2011; Sessink 2015;
Yoshida 2013). There are several guidelines for safe handling of
hazardous drugs including those issued by the UK Health and
Safety Executive (HSE), NHS Pharmaceutical Quality Assurance
Committee, US NIOSH, US Pharmacopeial Convention (USP),
Program in Evidence-Based Care guidelines, International Society
of Oncology Pharmacy Practitioners Standards, American Society
of Health-System Pharmacists, and Association paritaire pour la
santé et la sécurité du travail du secteur affaires sociales (ASST-
SAS) (ASSTSAS 2008; ASHP 2006; Bateman 2015; Easty 2015;
HSE 2017; ISOPP 2007; NIOSH 2004; USP 2017). Broadly,
these guidelines recommend the identification of the risk, use
of biological safety cabinets, use of closed-system drug-transfer
devices where reasonably practicable, and control of exposure at
source (e.g. by using adequate extraction systems and appropriate
organisational measures, issuing personal protective equipment,
monitoring exposure at the workplace, providing health surveil-
lance programmes, providing employee information and training,
maintaining equipment appropriately, having appropriate proce-
dures for dealing with spillages or contamination of people or
work surfaces, and providing safe waste disposal) (ASSTSAS2008;
ASHP 2006; Bateman 2015; Easty 2015; HSE 2017; ISOPP
2007; NIOSH 2004; USP 2017).
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Description of the intervention
A closed-system drug-transfer device is an apparatus that me-
chanically prohibits the transfer of environmental contaminants
into the system and the escape of hazardous drug or vapour out-
side the system (NIOSH 2004). Some examples of closed-system
drug-transfer devices are: PhaSeal system, ChemoClave system,
Equashield system, and Chemo Safety system. These devices in-
clude a method to access the intravenous infusion (e.g. a spike de-
signed to prevent leaks and spillages), and a leak-proof connection
that attempts to transfer drugs without leaks or spillage, as a min-
imum (B Braun 2017a; BD 2017a; BD 2017b; Equashield 2017;
ICUMED 2017). However, some devices used in compounding
hazardous drugs are not fully considered closed-systemdrug-trans-
fer devices, as they are not conceived or have not been demon-
strated to capture aerosols such as hydrophobic-air-venting filters
or chemotherapy transfer/reconstitution spikes (B Braun 2017b;
Healthmark 2017). In this review, we will accept any device de-
scribed as a closed-system drug-transfer device by the manufac-
turer.
How the intervention might work
Closed-system drug-transfer devices work by attempting to pro-
vide a leak-proof connection that prevents leaks and spills (B
Braun 2017a; BD2017a; BD2017b; Equashield 2017; ICUMED
2017). This may decrease surface contamination and atmospheric
contamination (with drug aerosol), thereby decreasing occupa-
tional exposure to infusional hazardous drugs. This in turn might
result in fewer adverse events related to exposure. In addition, the
systems also attempt to prevent microbiological contamination of
the drug (BD 2017a; Equashield 2017; ICUMED 2017), poten-
tially enabling reuse of vials and decreasing the costs.
Why it is important to do this review
There is significant variation in the way hazardous drugs are han-
dled by staff. Legislation requires organisations to protect workers’
health and safety (HSE 2017). All the staff working in hospitals
that administer hazardous drugs are at potential risk of exposure to
the drugs, which can result in the serious consequences described
above (see Description of the condition). Even when staff handle
hazardous drugs according to all instructions and as safely as possi-
ble, there is still the possibility of accidental contamination of sur-
faces around them, which exposes other staffmembers to the drugs
and their serious consequences. Therefore, it is important to use
themost effectivemethods to decrease the risk of staff contact with
infusional hazardous drugs. Some studies have shown that closed-
system drug-transfer devices may decrease surface contamination
compared to current safe handling practices including biological
safety cabinets and use of personal protective equipment (Harrison
2006; Sessink 2011).However, there are additional costs associated
with using closed-system drug-transfer devices compared to safe
handling of infusional hazardous drugs, and it is unclear whether
these devices provide good value for money (i.e. whether the cost-
benefit ratio is favourable to using closed-system drug-transfer de-
vices compared to conventional safe handling of infusional haz-
ardous drugs). There is alsomajor uncertainty about whether these
devices are effective in reducing the risk of exposure. In one study,
pharmacists considered that the use of a closed-system drug-trans-
fer device increased technical issues, increased the risk of spillage,
was slower and more cumbersome to use, and increased the risk of
drug absorption through the skin and by inhalation (Guillemette
2014). In addition, there is concern that the observed differences
in surface contamination attributed to the addition of closed-sys-
tem drug-transfer devices to safe handling could actually be due
to differences in the removal of previous drug residue. Further
concerns include the possible contamination of the exterior of
the hazardous drug vials at the manufacturing site (Connor 2005;
Favier 2003; Fleury-Souverain 2014;Hedmer 2005;Mason 2003;
Naito 2012), which may decrease the effectiveness of the closed-
system drug-transfer devices in real-life situations compared to
controlled laboratory situations. Several studies have shown high
levels of drug vial exterior contamination (Connor 2005; Favier
2003; Fleury-Souverain 2014; Hedmer 2005;Mason 2003; Naito
2012), although there are exceptions to this (Power 2014). The
risk of contamination may be dependent upon the manufacturing
process used, for example due to different decontamination proce-
dures and the encasing of the vials using protective sleeves (Connor
2005; Power 2014). Because of the uncertainty in the effective-
ness of the closed-system drug-transfer devices, there is variation
in the recommendations of different guidelines about the use of
these devices. For example, USP recommends mandatory use of
closed-system drug-transfer devices for administration when the
dosage form allows, while NIOSH only recommends considering
their use when transferring hazardous drugs (NIOSH 2004; USP
2017). Furthermore, the staff handling hazardous drugs may be
anxious about the serious consequences and want to know how
well these devices protect them. There is currently no systematic
review on the effect of closed-system drug-transfer devices versus
conventional safe handling for reducing the risk of staff contami-
nation to infusional hazardous drugs. This Cochrane Review will
provide the best available evidence regarding this issue.
O B J E C T I V E S
To assess the effects of closed-system drug-transfer of infusional
hazardous drugs plus safe handling versus safe handling alone for
reducing staff exposure to infusional hazardous drugs and risk of
staff contamination.
M E T H O D S
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Criteria for considering studies for this review
Types of studies
Due to the complex nature of the intervention, which is applied
at the group level in work situations rather than at the individual
level, randomised controlled trials (RCTs) are not very feasible,
which is one of the major reasons for including non-randomised
studies in Cochrane Reviews (Ijaz 2014). Therefore, we included
other study designs in addition to RCTs. We considered com-
parative studies that are commonly performed in this field, that
is, uncontrolled before-after studies and cohort studies. We also
included interrupted time-series, controlled before-after (CBA)
studies, and case-control studies. This is because interrupted time-
series may account for time trends in improvement of practices,
and CBA studies may account for any interim changes in policies.
We included case-control studies because the outcomes following
exposure are rare.
Types of participants
We included studies conducted on adult healthcare staff (aged 18
years or above) involved in the preparation, transport, delivery, ad-
ministration, and disposal of waste of infusional hazardous drugs.
We also considered healthcare organisations where healthcare staff
were exposed to infusional hazardous drugs as participants with
regards to outcomes such as surface contamination and aerosol
contamination.
Types of interventions
We included trials that evaluated the effectiveness of closed-sys-
tem drug transfer of infusional hazardous drugs (e.g. PhaSeal sys-
tem and ChemoClave system) plus safe handling of infusional
hazardous drugs (e.g. including class II biological safety cabinet,
isolator, and personal protective equipment) versus safe handling
alone. We accepted any device whose manufacturer described it as
a closed-system drug-transfer device. We included trials with any
co-interventions provided they were not part of the randomised
treatment or were applied equally in both arms in non-randomised
studies.
Types of outcome measures
Primary outcomes
• Measures of exposure to infusional hazardous drugs such as
urine mutagenicity, chromosomal aberrations, sister chromatid
exchanges, and micronuclei induction
• Environmental contamination measured with surrogate
outcomes for exposure: surface samples, splashes, leakage tests, or
atmospheric contamination
• Short-term health outcomes such as skin rashes
• Medium-term health outcomes such as infertility or
miscarriage
• Long-term health outcomes such as cancer (any type of
cancer)
We accepted any methods used by the study authors, for exam-
ple, routine screening for the presence or absence of outcomes or
assessment of these outcomes in only people with symptoms sug-
gestive of the presence of these outcomes. The Board of the UK
Oncology Nursing Society identified these outcomes as the most
important outcomes for the target population by as part of their
funding call.
Secondary outcomes
• Adverse events (e.g. personal injury due to the use of spikes
or needles resulting in infections)
• Potential cost savings due to reuse of multi-dose vials
We considered follow-up times for primary and secondary out-
come measurement as: short term (up to one year), medium term
(one to five years), and long term (longer than five years).
Reporting one or more of the primary or secondary outcomes
listed here is not an inclusion criterion for the review.
Search methods for identification of studies
Electronic searches
We conducted a systematic literature search to identify all pub-
lished and unpublished trials that were potentially eligible for in-
clusion in this review. We adapted the search strategy developed
for MEDLINE (see Appendix 1) for use in the other electronic
databases. We imposed no restrictions on language of publication
and translated the key sections of potentially eligible non-English
language papers to assess them fully for potential inclusion in the
review as necessary.
We searched the following electronic databases from inception to
26 October 2017 to identify potential studies. The only exception
was the databases searched through OSH-UPDATE search plat-
form, which we searched on 3 October 2017.
• Cochrane Central Register of Controlled Trials
(CENTRAL) (Wiley Online Library) (Appendix 2).
• MEDLINE (OvidSP) (Appendix 1).
• Embase (OvidSP) (Appendix 3).
• NIOSHTIC (OSH-UPDATE) (Appendix 4).
• NIOSHTIC-2 (OSH-UPDATE) (Appendix 4).
• HSELINE (OSH-UPDATE) (Appendix 4).
• CISDOC (OSH-UPDATE) (Appendix 4).
• CINAHL (EBSCO) (Appendix 5).
• Science Citation Index Expanded (including Conference
Proceedings) (Appendix 6).
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• NHS Economic Evaluation Database (NHS EED)
(Appendix 7).
• Cost-Effectiveness Analysis Registry (CEA) at Tufts
University (Appendix 7).
We also conducted a search for unpublished trials in ClinicalTri-
als.gov (www.clinicaltrials.gov) and the World Health Organiza-
tion (WHO) trials portal (www.who.int/ictrp/en/) (Appendix 8)
on 26 October 2017.
Searching other resources
We checked reference lists of all primary studies and review arti-
cles for additional references and contacted experts in the field to
identify additional unpublished material.
Data collection and analysis
Selection of studies
We conducted the selection of eligible studies in two stages. First,
two review authors (KG and LB) independently screened titles
and abstracts of all potentially relevant studies found with our
systematic search to exclude studies that clearly did not fulfil the
criteria for inclusion. CT identified additional studies by review-
ing bibliographies to identify further full-text records for poten-
tial inclusion. The same review authors coded records as ’include’
(eligible or potentially eligible/unclear) or ’exclude’. We excluded
all references that clearly did not fulfil our inclusion criteria or
that fulfilled our exclusion criteria. Second, we retrieved the full-
text study reports/publications, and two review authors (KG and
LB) independently assessed the full-text to identify studies for in-
clusion. At this stage, we included all references that fulfilled our
inclusion criteria. We recorded reasons for excluding studies based
on assessment of the full text and reported these in a ’Character-
istics of excluded studies’ table. We resolved any disagreements
through discussion. We identified and excluded duplicates and
collated multiple reports of the same study so that each study
rather than each report was the unit of interest in the review. We
recorded the selection process in sufficient detail to complete a
PRISMA study flow diagram.
Data extraction and management
We used an Excel-based data collection form for study character-
istics and outcome data that was piloted on two studies in the
review. Two review authors (KG and LB) extracted the following
study characteristics from included studies.
• Methods: study design, duration of study, study location,
study setting, withdrawals, and date of study.
• Participants: number of participants, number of clusters
(hospitals or wards), mean age or age range, sex, inclusion
criteria, and exclusion criteria.
• Interventions: description of intervention, comparison
(elements included in safe handling in the control group), and
co-interventions.
• Outcomes: description of primary and secondary outcomes
specified and collected, and at which time points reported.
• Notes: funding for trial, and notable conflicts of interest of
trial authors.
Two review authors (KG and LB) independently extracted out-
come data from included studies. We noted in the ’Characteristics
of included studies’ table if authors did not report outcome data in
a usable way.We resolved disagreements by consensus. One review
author (KG) transferred data into Review Manager 5 (RevMan
2014). We double-checked the data entry by comparing the data
presented in the systematic review with the study reports. A third
review author (CT) spot-checked study characteristics and data for
accuracy against the trial report. The author team was proficient
in all languages of the studies included in the review (English and
French).
Assessment of risk of bias in included studies
For each RCT, two review authors (KG and LB) independently
planned to assess risk of bias using criteria outlined in theCochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We planned to resolve any disagreements by discussion. We
planned to assess the risk of bias according to the following do-
mains.
• Random sequence generation.
• Allocation concealment.
• Blinding of participants and personnel.
• Blinding of outcome assessment.
• Incomplete outcome data.
• Selective outcome reporting.
• Other bias (including source of funding and whether the
duration of exposure to hazardous drugs in the intervention
group and control group was measured reliably after ensuring
that the participants were free from the outcome at the
beginning of the study).
We planned to grade each potential risk of bias as high, low, or
unclear, and we provided a quotation from the study report to-
gether with a justification for our judgement in the ’Risk of bias’
table. We planned to summarise the risk of bias judgements across
different studies for each of the domains listed. We planned to
consider blinding separately for different key outcomes where nec-
essary. To classify studies as being at low risk of bias in measure-
ment of outcome, we required them to have carried out blinded
assessment of all outcomes except for contamination of surface
samples, where we accepted samples obtained and analysed by an
automated machine as being at low risk of bias regardless of blind-
ing. For urinary levels, we accepted this outcome as being at low
risk of bias regardless of blinding. Where information on risk of
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bias relates to unpublished data or correspondence with a trialist,
we planned to note this in the ’Risk of bias’ table.
For each non-randomised study, the same two review authors (KG
and LB) assessed the risk of bias independently using the risk of
bias in non-randomised studies of interventions (ROBINS-I) tool
(Sterne 2016). We considered the following as possible sources of
confounding.
• Changes or differences in other factors for genetic and
chromosomal damage such as stress from work, working long
hours, and smoking that might lead to fewer genetic and
chromosomal abnormalities compared to the intervention.
• Differences in drug residue on a surface prior to
contamination (e.g. thorough cleaning before the study in only
one group).
• Changes or differences in drug residue on the drug vials
because of different batches or different manufacturers of the
drug.
In terms of bias due to classification of interventions, we consid-
ered studies to be at low risk of bias when it was clear that the in-
tervention group was CSTD and the control group was no CSTD.
We considered the following co-interventions.
• Changes or differences in layout, ventilation, fume
cupboards, etc., that might lead to less contamination compared
to the intervention.
• Changes or differences in policies that might lead to less
contamination compared to the intervention.
• Education, training, and experience of healthcare staff that
might lead to less contamination compared to the intervention.
• Differences in the supervision for drug preparation or drug
administration that might lead to less contamination compared
to the intervention.
We planned to assess the risk of bias in the included economic
evaluations using either the Consensus Health Economic Criteria
(CHEC) list for assessment ofmethodological quality of economic
evaluations, described in Evers 2005, or the Philips 2004 checklist.
We considered all domains other than blinding of healthcare
providers to be key domains. We judged a study to be at high risk
of bias overall when we judged one or more key domains to be at
high risk of bias. Conversely, we judged a study to be at low risk
of bias when we assigned a low risk of bias for all key domains.
When considering treatment effects, we took into account the risk
of bias for the studies that contributed to that outcome.
Assessment of bias in conducting the systematic
review
We conducted the review according to the published protocol and
reported any deviations from it in Differences between protocol
and review.
Measures of treatment effect
We entered the outcome data for each study into the data tables in
RevMan 5 to calculate the treatment effects unadjusted for clus-
tering (RevMan 2014). As we did not find any case-control stud-
ies, we used the risk ratio (RR) for dichotomous outcomes (this
is because RRs are much easier to interpret; however, they can-
not be calculated in case-control studies without the use of risk
from another study), and mean differences (MDs) for continuous
outcomes. If studies reported only effect estimates and their 95%
confidence intervals (CIs) or standard errors, we planned to en-
ter these data into RevMan 5 using the generic inverse variance
method (RevMan 2014). We ensured that higher scores for con-
tinuous outcomes have the same meaning for the particular out-
come. When the results could not be entered in either way, we
entered the data into additional tables.
For interrupted time-series studies, we extracted data from the
original papers and reanalysed them according to the recom-
mended methods for analysing interrupted time-series designs for
inclusion in systematic reviews (Ramsay 2003). We planned to
use the standardised change in level and change in slope as effect
measures.
Unit of analysis issues
For studies that employed a cluster-design and reported sufficient
data to be included in the meta-analysis but did not make an al-
lowance for the design effect, we calculated the design effect based
on a fairly large assumed intracluster correlation coefficient (ICC)
of 0.10.We based this assumption of 0.10 being a realistic estimate
by analogy with studies about implementation research (Campbell
2001).We followed the methods stated in theCochrane Handbook
for Systematic Reviews of Interventions for the calculations, and we
entered the data adjusted for clustering as generic inverse variance
data (Higgins 2011). This involved calculating the average clus-
ter size ’M’ (by dividing the total number of samples by the total
number of hospitals) and calculating the design effect by using the
formula 1 + (M − 1) ICC. We multiplied the standard error for
each cluster study by the square root of the design effect to obtain
a standard error adjusted for clustering. This adjusted standard
error was then used to calculate the confidence intervals.
Dealing with missing data
We contacted investigators or study sponsors to verify key study
characteristics and obtain missing numerical outcome data where
possible (e.g. when a study was reported as abstract only). Where
this was not possible, and if the missing data were thought to in-
troduce serious bias, we would have explored the impact of includ-
ing such studies in the overall assessment of results by a sensitivity
analysis.
If numerical outcome data were missing, such as standard devia-
tions or correlation coefficients, and they could not be obtained
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from the authors, we planned to calculate them from other avail-
able statistics such as P values, according to the methods described
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).
Assessment of heterogeneity
We assessed the clinical homogeneity of the results of included
studies based on similarity of population, intervention, outcome,
and follow-up. We considered populations as similar when they
were staff who were exposed to infusional hazardous drugs, for
example, oncology nurses, pharmacy technicians, or pharmacists
who handled infusional hazardous drugs.We considered interven-
tions as similar when it was clear that the system was a closed-sys-
tem drug transfer device. We combined results data produced by
each of the measures of contamination separately (e.g. urine tests,
surface contamination, and atmospheric contamination), and we
planned to combine cancer- and fertility-related outcome data sep-
arately. We considered short-term (up to one year), medium-term
(one to five years), and long-term (more than five years) follow-
up times as different.
We used the I² statistic to measure heterogeneity among the trials
in each analysis. If we identified substantial heterogeneity (above
50%, as described in Higgins 2011), we planned to report it and
explore possible causes by prespecified subgroup analysis.
Assessment of reporting biases
If we were able to pool more than five trials in any single meta-
analysis, we created and examined a funnel plot to explore possi-
ble small-study biases. We used Egger’s test to identify reporting
biases (Egger 1997). We considered a P value of less than 0.05 as
statistically significant reporting bias.
Data synthesis
We pooled data from studies we judged to be clinically homoge-
neous using RevMan 5 software (RevMan 2014). If two or more
studies provided usable data in any single comparison, we per-
formedmeta-analyses.However, we did not plan to pool data from
different study designs (i.e. RCT and non-randomised studies).
We analysed different drugs in separate analyses since drugs are
reconstituted differently, administered differently (for example,
some are intravenous only while others can be used intravenously,
subcutaneously, or orally), used in different quantities, and can
lead to different levels of exposure and contamination. Further-
more, these are dangerous at different dosages. In addition, we
analysed the pharmacy areas and patient-care areas separately since
the levels of exposure and contamination vary between them.
For costs, we used an international exchange rate based on pur-
chasing power parities (PPP) to convert cost estimates to US dol-
lars (USD), and we used the gross domestic product (GDP) defla-
tors (or implicit price deflators for GDP) to convert cost estimates
to 2017 USD using PPP conversion rates and GDP deflator values
available from the InternationalMonetary Fund in theWorld Eco-
nomic Outlook Database (updated biannually: see www.imf.org/
external/data.htm). We used both a fixed-effect model and a ran-
dom-effects model to perform the meta-analyses and reported the
more conservative model. When the I² statistic was higher than
75%, we did not plan to pool results of studies in meta-analysis.
Where a single trial reported multiple trial arms, we included only
the relevant arms. If two comparisons (e.g. device A versus safe
handling and device B versus safe handling) were combined in
the same meta-analysis, we planned to halve the control group to
avoid double-counting.
Subgroup analysis and investigation of heterogeneity
We planned to carry out the following subgroup analyses.
• Study design: CBA studies versus other non-randomised
study designs; individual versus cluster unit of analysis. These
were planned subgroup analyses. We also performed a post hoc
subgroup analysis of uncontrolled before-after studies versus
cross-sectional studies, as these were the two types of studies that
contributed data for the analysis. This analysis can assess the
impact of trend in improving safe handling practices that could
be problematic in uncontrolled before-after studies.
• Professional role: pharmacy technician versus
chemotherapy nurse versus other healthcare staff.
• Duration of possible exposure.
• Intervention: any closed-system drug-transfer device.
• Control: safe handling following UK HSE standards.
We planned to perform subgroup analyses for primary outcomes
(i.e. immediate to short-term contamination, short-term health
benefits, long-term reproductive health benefits, and development
of any type of cancers). We planned to use the Chi² test to test for
subgroup interactions in Review Manager 5 (RevMan 2014).
Sensitivity analysis
Weplanned to perform a sensitivity analysis involving studies with
low risk of bias versus studies with high risk of bias defined a priori
to assess the robustness of our conclusions.
We performed a post hoc sensitivity analysis to assess the impact
of the influence of different intracluster correlation coefficients on
the results to determine if the differences in conclusions between
our systematic review and primary research studies could be due to
the lack of adjusting for cluster effect in primary research studies.
Summary of findings table
We created a ’Summary of findings’ table using all outcomes (i.e.
exposure, environmental contamination, health outcomes, adverse
events, and potential cost savings). We used the five GRADE con-
siderations (study limitations, consistency of effect, imprecision,
indirectness, and publication bias) to assess the quality of a body
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of evidence as it related to the studies that contributed data to the
meta-analyses for the prespecified outcomes. We used methods
and recommendations described in Section 8.5 and Chapter 12
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011), using GRADEpro software (GRADEpro GDT).
We justified all decisions to downgrade or upgrade the quality of
studies using footnotes.
Since we described all the decisions to downgrade or upgrade the
quality of studies using the footnotes and described the reason
in detail under each outcome in the text, we did not compile
an additional GRADE table showing all our decisions about the
quality of evidence and their justifications.
Reaching conclusions
Webased our conclusions only onfindings from the quantitative or
narrative synthesis of included studies for this review. We avoided
making recommendations for practice based onmore than just the
evidence, such as values and available resources. Our implications
for research suggest priorities for future research and outline what
the remaining uncertainties are in the area.
R E S U L T S
Description of studies
Results of the search
We identified a total of 9033 records from CENTRAL (70 ref-
erences), MEDLINE (695 references), Embase (1043 references),
OSH-UPDATE (8 references), CINAHL (253 references), Sci-
ence Citation Index Expanded (including Conference Proceed-
ings) (6830 references), NHS EED (0 references), CEA at Tufts
University (0 references), ClinicalTrials.gov (131 references), and
the World Health Organization (WHO) trials portal (3 refer-
ences). After excluding 1463 duplicate records and seeking 17
other references based on handsearching, we screened the titles and
abstracts of 7587 records. We obtained full texts for 83 potentially
eligible studies. Of these, we excluded 56 references for the reasons
detailed in Characteristics of excluded studies and summarised in
Excluded studies. In total, we included 23 studies (27 references).
See the study inclusion process explained in Figure 1.
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Figure 1. PRISMA study flow diagram. CSTD: closed-system transfer device
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Included studies
All 23 included studies are cluster studies, that is, the comparison
is between hospitals that used CSTD versus those that did not
(cross-sectional studies) or between the period inwhichCSTDwas
used versus the period in which it was not (interrupted time-series
or uncontrolled before-after studies). Of the 23 included studies,
1 study (3 hospitals) is an interrupted time-series (Harrison 2006),
13 (65hospitals) are uncontrolled before-after studies (Chan 2016;
Edwards 2013; Guillemette 2014; Hama 2012; Juhasz 2016;
Miyake 2013;Mullot 2008;Ozyaman2016; Sessink 2011; Sessink
2013; Siderov 2010; Wick 2003; Yoshida 2009), and 9 (290 hos-
pitals) are cross-sectional studies (Berruyer 2015; Chauchat 2017;
Forges 2011; Janes 2015; Poupeau 2016; Roland 2017; Simon
2016; Sottani 2012; Yoshida 2011). In one cross-sectional study, a
hospital used the same isolators during the same period to prepare
drugs using CSTD and no CSTD (Forges 2011). In another, the
same hospital used two different isolators to prepare drugs over
the same period: CSTD in one isolator and no CSTD in the other
(Simon 2016). In the remaining seven cross-sectional studies, 91
hospitals used CSTD and 197 hospitals did not (Berruyer 2015;
Chauchat 2017; Janes 2015; Poupeau 2016; Roland 2017; Sottani
2012; Yoshida 2011). We did not find any randomised controlled
trials or formal economic evaluations. Overall, 358 hospitals in
Australia, Canada, France,Hungary, Italy, Japan,Malaysia, Turkey,
and the USA took part. Most hospitals were from Canada and
the USA. There was also an overlap between hospitals included in
the different studies, although there was minimal or no overlap in
the period when the samples were collected (i.e. the samples were
included only once in the analysis).
In 21 studies, the people who used the intervention (CSTD
plus safe handling) and control (safe handling alone) were phar-
macists or pharmacy technicians (Berruyer 2015; Chan 2016;
Chauchat 2017; Edwards 2013; Forges 2011; Guillemette 2014;
Hama 2012; Harrison 2006; Janes 2015; Juhasz 2016; Miyake
2013;Ozyaman2016; Poupeau 2016;Roland 2017; Sessink 2011;
Sessink 2013; Siderov 2010; Simon 2016; Sottani 2012; Yoshida
2009; Yoshida 2011); in two studies, the people who used the in-
tervention and control were nurses in addition to pharmacists or
pharmacy technicians (Mullot 2008; Wick 2003).
The CSTDs used in the studies were PhaSeal (13 studies: Chan
2016; Edwards 2013; Guillemette 2014; Hama 2012; Harrison
2006; Miyake 2013; Ozyaman 2016; Sessink 2011; Sessink 2013;
Siderov 2010; Simon 2016; Wick 2003; Yoshida 2009), Tevadap-
tor (1 study: Juhasz 2016), SpikeSwan (1 study: Forges 2011),
PhaSeal and Tevadaptor (1 study: Mullot 2008), varied (5 stud-
ies: Berruyer 2015; Chauchat 2017; Janes 2015; Poupeau 2016;
Roland 2017), and not stated (2 studies: Yoshida 2011; Sottani
2012). The descriptions of the control groups varied; although we
provide the details reported in Characteristics of included studies,
additional safety measures are likely to have been in place.
The outcomes reported in the studies are exposure (4 studies:
Miyake 2013; Sottani 2012; Wick 2003; Yoshida 2009), surface
contamination (16 studies: Berruyer 2015;Chauchat 2017; Forges
2011; Guillemette 2014; Harrison 2006; Janes 2015; Miyake
2013; Poupeau 2016; Roland 2017; Sessink 2011; Sessink 2013;
Siderov 2010; Simon 2016; Sottani 2012; Wick 2003; Yoshida
2009), and potential cost savings (5 studies: Chan 2016; Edwards
2013; Juhasz 2016; Mullot 2008; Ozyaman 2016). None of the
studies that report exposure reported the intracluster correlation
coefficient. The remaining two studies did not report the outcomes
in a format that could be tabulated or pooled with meta-analysis,
as key information was missing and we were unable to obtain it
from study authors (Hama 2012; Yoshida 2011).
The duration of exposure of people toCSTDand controlmeasures
is relevant only for studies that reported the presence of hazardous
drugs in urine (Miyake 2013; Sottani 2012; Wick 2003; Yoshida
2009). This was seven months in Miyake 2013; not reported in
Sottani 2012; six months to CSTD without any information on
the duration of exposure in the control group in Wick 2003; and
two weeks in Yoshida 2009.
With regard to funding, eight studies received no special fund-
ing (Berruyer 2015; Chauchat 2017; Edwards 2013, Guillemette
2014, Janes 2015, Juhasz 2016; Poupeau 2016; Roland 2017), six
studies received funding from manufacturers of the device being
evaluated (Harrison 2006; Sessink 2011; Sessink 2013; Siderov
2010; Simon 2016; Wick 2003), and the remaining nine stud-
ies did not report funding (Chan 2016; Forges 2011; Hama
2012; Miyake 2013; Mullot 2008; Ozyaman 2016; Sottani 2012;
Yoshida 2009; Yoshida 2011).
Excluded studies
We excluded 56 studies after full-text assessment (Characteristics
of excluded studies). Themain reasons for exclusion are as follows.
• Not a primary research study: eight studies (Hospital
Infection Control 2005; Kunneva 2016; Laws 2016; Lennan
2017; Meade 2015; Oncology Nurse Advisor 2017; Talsmar
2015).
• Not a study comparing CSTD plus standard care versus
standard care: 16 studies (Clark 2013; Connor 2010; Contractor
2015; Cox 2017; Enciso-Zarate 2016; Gilles 2009; Hong 2017;
Idell 2009; Kopp 2013; Kurihara 2017; Nygren 2005; Nyman
2007; Odraska 2013; Sessink 1999; Tyler 2017; Yoshida 2013).
This reason encompasses studies that introduced other safety
measures such as biosafety cabinets or change in the layout of the
pharmacy in addition to CSTD as well as studies that cleaned
the surfaces for only the CSTD group prior to exposure to
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hazardous drugs, which clearly does not estimate the benefits or
harms of CSTD plus safe handling versus safe handling alone.
• Simulation study: 29 studies (Blazawski 2013; Chantry
2015; De Ausen 2013; De Prijck 2008; DeFreitas 2012; Favier
2012; Fernandez 2013; Garrigue 2016; Gebel 2015;
Gomez-Alvarez 2016; Gonzalez-Haba Pena 2016; Hama 2011;
Ikeno 2014; Jorgenson 2008; Le Garlantezec 2011; Lin 2017;
McMichael 2011; Nishigaki 2010; Nygren 2008; Perlo 2015;
Queruau Lamerie 2012; Rupp 2017; Sanchez-Rubio Ferrandez
2012; Sanchez-Rubio Ferrandez 2012; Sato 2010; Simon 2010;
Smith 2014; Thomas Carey 2011; Vyas 2016).
• Comparison of different CSTDs: two studies (Amos 2012;
Ledford 2010).
• Intermittent use of CSTD (not possible to determine
whether the outcomes were for CSTD or standard care): one
study (McDiarmid 2010).
Risk of bias in included studies
The risk of bias in the included studies is summarised in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study. Green +: Low risk of bias. Yellow ?: Moderate risk of bias or ’No information’. Red -: Serious or critical
risk of bias.
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Confounding bias
There is insufficient information to assess the risk of confounding
bias in all the studies (Berruyer 2015; Chan 2016; Chauchat 2017;
Edwards 2013; Forges 2011; Guillemette 2014; Hama 2012;
Harrison 2006; Janes 2015; Juhasz 2016; Miyake 2013; Mullot
2008;Ozyaman2016; Poupeau 2016;Roland 2017; Sessink 2011;
Sessink 2013; Siderov 2010; Simon 2016; Sottani 2012; Wick
2003; Yoshida 2009; Yoshida 2011). This is because none of the
studies reported whether there were any baseline differences in any
of the confounding factors.
Selection bias
Thirteen studies are at low risk of selection bias (Chan 2016;
Edwards 2013; Forges 2011; Hama 2012; Harrison 2006; Juhasz
2016; Miyake 2013;Mullot 2008; Ozyaman 2016; Siderov 2010;
Simon 2016;Wick 2003; Yoshida 2009). Nine studies are at mod-
erate risk of selection bias, as the participating centres were proba-
bly selected or returned the questionnaire about CSTD use based
on their safe handling practices (Berruyer 2015; Chauchat 2017;
Janes 2015; Poupeau 2016; Roland 2017; Sessink 2011; Sessink
2013; Sottani 2012; Yoshida 2011). One study is at serious risk of
bias as the sites of sampling differed between CSTD and control
groups (Guillemette 2014). None of the studies are at critical risk
of bias.
Bias in classification of interventions
All the studies are at low risk of bias since the classification of
CSTD versus control was made clearly (Berruyer 2015; Chan
2016; Chauchat 2017; Edwards 2013; Forges 2011; Guillemette
2014; Hama 2012; Harrison 2006; Janes 2015; Juhasz 2016;
Miyake 2013; Mullot 2008; Ozyaman 2016; Poupeau 2016;
Roland 2017; Sessink 2011; Sessink 2013; Siderov 2010; Simon
2016; Sottani 2012; Wick 2003; Yoshida 2009; Yoshida 2011).
Bias due to deviations from intended interventions
There is insufficient information to assess the risk of bias
due to deviations from intended interventions in 16 studies
(Berruyer 2015; Chan 2016; Chauchat 2017; Edwards 2013;
Hama 2012; Harrison 2006; Janes 2015; Juhasz 2016; Ozyaman
2016; Poupeau 2016; Roland 2017; Sessink 2011; Sessink 2013;
Siderov 2010; Sottani 2012; Yoshida 2011), as they did not report
whether the training periods and other co-interventions were sim-
ilar in both groups. The remaining seven studies are at serious risk
of bias, since it is clear that only CSTD groups received additional
training while the control group did not receive an equivalent pe-
riod of training in safe handling (Forges 2011; Guillemette 2014;
Miyake 2013; Mullot 2008; Simon 2016; Wick 2003; Yoshida
2009).
Bias due to missing data
Seventeen studies are at low risk of bias due to missing data (Chan
2016; Chauchat 2017; Edwards 2013; Guillemette 2014; Juhasz
2016; Miyake 2013; Mullot 2008; Ozyaman 2016; Roland 2017;
Sessink 2011; Sessink 2013; Siderov 2010; Simon 2016; Sottani
2012; Wick 2003; Yoshida 2009; Yoshida 2011). There is insuf-
ficient information to assess the risk of bias in the remaining six
studies (Berruyer 2015; Forges 2011; Hama 2012;Harrison 2006;
Janes 2015; Poupeau 2016), as there is either missing information,
the impact of which on the effect estimates is not clear, or it is not
clear whether there is missing information in the studies.
Bias in measurement of outcomes
All 23 studies are at serious risk of bias in measurement of out-
comes as it appears that none of the studies used blinded assess-
ment of outcomes (Berruyer 2015; Chan 2016; Chauchat 2017;
Edwards 2013; Forges 2011; Guillemette 2014; Hama 2012;
Harrison 2006; Janes 2015; Juhasz 2016; Miyake 2013; Mullot
2008;Ozyaman2016; Poupeau 2016;Roland 2017; Sessink 2011;
Sessink 2013; Siderov 2010; Simon 2016; Sottani 2012; Wick
2003; Yoshida 2009; Yoshida 2011).
Bias in selection of the reported result
Six studies are at low risk of bias in selection of the reported result
(Forges 2011; Miyake 2013; Siderov 2010; Sottani 2012; Wick
2003; Yoshida 2009). The remaining 17 studies are at serious risk
of bias in selection of the reported result: they report results par-
tially (Berruyer 2015; Chan 2016; Chauchat 2017; Edwards 2013;
Guillemette 2014;Hama2012;Harrison 2006; Janes 2015; Juhasz
2016;Mullot 2008;Ozyaman2016; Poupeau 2016; Roland 2017;
Sessink 2011; Sessink 2013; Simon 2016; Yoshida 2011).
Overall risk of bias
All the studies are at serious risk of bias (Berruyer 2015; Chan
2016; Chauchat 2017; Edwards 2013; Forges 2011; Guillemette
2014; Hama 2012; Harrison 2006; Janes 2015; Juhasz 2016;
Miyake 2013; Mullot 2008; Ozyaman 2016; Poupeau 2016;
Roland 2017; Sessink 2011; Sessink 2013; Siderov 2010; Simon
2016; Sottani 2012; Wick 2003; Yoshida 2009; Yoshida 2011).
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Effects of interventions
See: Summary of findings for the main comparison Closed-
system transfer device plus safe handling versus safe handling alone
for reducing healthcare staff exposure to infusional hazardous
drugs: exposure and surface contamination; Summary of findings
2 Closed-system transfer device plus safe handling versus safe
handling alone for reducing healthcare staff exposure to infusional
hazardous drugs: clinical outcomes




Presence of hazardous drugs in urine
Four studies (seven hospitals; 70 participants) report the propor-
tion of people with positive urine tests for exposure (Miyake 2013;
Sottani 2012; Wick 2003; Yoshida 2009). One study is a cross-
sectional study involving four hospitals (Sottani 2012). The other
studies are uncontrolled before-after studies, each involving a sin-
gle hospital (Miyake 2013; Wick 2003; Yoshida 2009). The drugs
measured in these trials are cyclophosphamide alone in two studies
(Miyake 2013; Yoshida 2009), cyclophosphamide or ifosfamide
in one study (Wick 2003), and cyclophosphamide, ifosfamide, or
gemcitabine in one study (Sottani 2012). There is no evidence of
differences in the proportion of people with positive urine tests
for exposure between the CSTD and control groups for cyclo-
phosphamide alone (RR 0.83, 95% CI 0.46 to 1.52; I² = 0%; 2
studies; 2 hospitals; 20 participants); cyclophosphamide or ifos-
famide (RR 0.09, 95% CI 0.00 to 2.79;1 study; 1 hospital; 14
participants); and cyclophosphamide, ifosfamide, or gemcitabine
(RR not estimable; 1 study; 4 hospitals; 36 participants) (Analysis
1.1). There is no alteration in the interpretation of results using
the fixed-effect or the random-effects model.
Quality of evidence: the quality of evidence is very low because of
the serious risk of bias in the studies (downgraded by one level),
imprecision (small sample size (downgraded by one level) andwide
confidence intervals (downgraded by one level)).
Subgroup analysis: since there is only one cross-sectional study and
this is the only study examining cyclophosphamide, ifosfamide,
or gemcitabine, we did not perform a subgroup analysis of uncon-
trolled before-after studies versus cross-sectional studies. PhaSeal
was used in three studies (Miyake 2013; Wick 2003; Yoshida
2009). The authors of the fourth study did not report which de-
vice they used (Sottani 2012). There is no evidence of differences
in the proportion of people with positive urine tests for exposure
between the PhaSeal and control groups (Analysis 2.1).
Sensitivity analysis: There is also no alteration in the interpretation
of results using different intracluster correlation coefficients (ICC)
(Analysis 3.1; Analysis 3.2; Analysis 3.3).
Other measures of exposure
None of the studies reported on blood tests or other measures of
exposure to infusional hazardous drugs such as urine mutagenic-
ity, chromosomal aberrations, sister chromatid exchanges, or mi-
cronuclei induction.
Environmental contamination
Proportion of surfaces contaminated in pharmacy areas
Fourteen studies (342 hospitals, 3096 surface samples) report
the proportion of surface samples that were contaminated with
various drugs in the pharmacy areas (Berruyer 2015; Chauchat
2017; Guillemette 2014; Janes 2015; Miyake 2013; Poupeau
2016; Roland 2017; Sessink 2011; Sessink 2013; Siderov 2010;
Simon 2016; Sottani 2012; Wick 2003; Yoshida 2009). Seven
are cross-sectional studies involving 284 hospitals (Berruyer 2015;
Chauchat 2017; Janes 2015; Poupeau 2016; Roland 2017; Simon
2016; Sottani 2012), and seven are uncontrolled before-after
studies involving 58 hospitals (Guillemette 2014; Miyake 2013;
Sessink 2011; Sessink 2013; Siderov 2010; Wick 2003; Yoshida
2009). There is no evidence of difference in proportion of surface
samples that were contaminated between the CSTD and the con-
trol groups for any of the drugs in the pharmacy areas (Analysis
1.2).
• Cyclophosphamide: RR 0.89, 95% CI 0.78 to 1.01; I² =
35% (13 studies: 7 uncontrolled before-after studies (Guillemette
2014; Miyake 2013; Sessink 2011; Sessink 2013; Siderov 2010;
Wick 2003; Yoshida 2009); 6 cross-sectional studies (Berruyer
2015; Chauchat 2017; Janes 2015; Poupeau 2016; Roland 2017;
Simon 2016); 338 hospitals, 2937 surface samples).
• Ifosfamide: RR 0.94, 95% CI 0.74 to 1.19; I² = 8% (9
studies: 3 uncontrolled before-after studies (Guillemette 2014;
Sessink 2011; Wick 2003); 6 cross-sectional studies (Berruyer
2015; Chauchat 2017; Janes 2015; Poupeau 2016; Roland 2017;
Simon 2016); 304 hospitals, 2332 surface samples).
• Methotrexate: RR 0.84, 95% CI 0.58 to 1.22; I² = 0% (6
studies: 1 uncontrolled before-after study (Guillemette 2014); 5
cross-sectional studies (Berruyer 2015; Chauchat 2017; Janes
2015; Poupeau 2016; Roland 2017); 280 hospitals, 1781 surface
samples).
• 5-fluorouracil: RR 0.65, 95% CI 0.43 to 0.97; I² = 0% (3
studies: 1 uncontrolled before-after study (Sessink 2011); 2
cross-sectional studies (Chauchat 2017; Simon 2016); 106
hospitals, 1008 surface samples).
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• Cytarabine: RR 0.72, 95% CI 0.18 to 2.86; I² = 43% (2
studies: all cross-sectional studies (Chauchat 2017; Simon 2016);
84 hospitals, 780 surface samples).
• Gemcitabine: RR 0.96, 95% CI 0.60 to 1.54; I² = 0% (2
cross-sectional studies (Chauchat 2017; Simon 2016); 84
hospitals, 780 surface samples).
• Irinotecan: RR 0.36, 95% CI 0.10 to 1.33 (1 cross-sectional
study (Chauchat 2017); 83 hospitals, 493 surface samples).
• Docetaxel: not estimable (1 cross-sectional study (Chauchat
2017); 83 hospitals, 493 surface samples).
• Paclitaxel: RR 0.57, 95% CI 0.04 to 9.06 (1 cross-sectional
study (Chauchat 2017); 83 hospitals, 493 surface samples).
• Vinorelbine: RR 1.72, 95% CI 0.16 to 18.73 (1 cross-
sectional study (Chauchat 2017); 83 hospitals, 493 surface
samples).
• Ganciclovir: RR 0.01, 95% CI 0.00 to 27.11 (1 cross-
sectional study (Simon 2016); 1 hospital, 287 surface samples).
• Multiple drugs (data on each drug were not available): RR
0.87, 95% CI 0.43 to 1.77 (1 cross-sectional study (Sottani
2012); 4 hospitals, 109 surface samples).
There is no alteration in the interpretation of results using the
fixed-effect or the random-effects model.
Quality of evidence: the quality of evidence is very low because
of the serious risk of bias in all the studies (downgraded by one
level); indirectness of the outcome, as all the outcomes reported are
surrogate outcomes (downgraded by one level); and imprecision
because of wide confidence intervals (downgraded by one level)
or lack of evidence that the observed difference led to decreased
exposure or tangible health benefits (downgraded by one level).
Subgroup analysis: there is no evidence of subgroup differences in
the analyses that could be stratified by study design (uncontrolled
before-after versus cross-sectional studies) (Analysis 2.2; Analysis
2.3; Analysis 2.4; Analysis 2.5). The device used in eight stud-
ies was PhaSeal (Guillemette 2014; Miyake 2013; Sessink 2011;
Sessink 2013; Siderov 2010; Simon 2016; Wick 2003; Yoshida
2009). The devices used in five studies were variable (Berruyer
2015; Chauchat 2017; Janes 2015; Poupeau 2016; Roland 2017).
The last study did not report the device used in the study (Sottani
2012). There is no evidence of difference in proportion of surface
samples that were contaminated between the PhaSeal and the con-
trol groups for any of the drugs other than cyclophosphamide (RR
0.88, 95% CI 0.78 to 0.99; 8 studies; 59 hospitals, 1278 surface
samples; Analysis 2.6).
Sensitivity analysis: there is also no alteration in the interpretation
of results using different ICCs except for cyclophosphamide and
5-fluorouracil for intracluster coefficients of 0.05, 0.01, and 0.00,
and for ganciclovir for ICCs of 0.01 and 0.00 (Analysis 3.4;
Analysis 3.5; Analysis 3.6).
Proportion of surfaces contaminated in patient-care areas
Six studies (283 hospitals, 1568 surface samples) reported the pro-
portion of surface samples that were contaminated with various
drugs in the patient-care areas (Berruyer 2015; Chauchat 2017;
Janes 2015; Poupeau 2016; Roland 2017; Sottani 2012). There
was no evidence of difference in the proportion of surface sam-
ples that were contaminated with various drugs in the patient-care
areas between the CSTD and control groups in the patient-care
areas (Analysis 1.2).
• Cyclophosphamide: RR 1.01, 95% CI 0.86 to 1.18; I² =
0% (5 cross-sectional studies (Berruyer 2015; Chauchat 2017;
Janes 2015; Poupeau 2016; Roland 2017); 279 hospitals, 1535
surface samples).
• Ifosfamide: RR 1.44, 95% CI 0.91 to 2.28; I² = 20% (5
cross-sectional studies (Berruyer 2015; Chauchat 2017; Janes
2015; Poupeau 2016; Roland 2017); 279 hospitals, 1535 surface
samples).
• Methotrexate: RR 1.00, 95% CI 0.55 to 1.85; I² = 0% (5
cross-sectional studies (Berruyer 2015; Chauchat 2017; Janes
2015; Poupeau 2016; Roland 2017); 279 hospitals, 1535 surface
samples).
• 5-fluorouracil: RR 1.09, 95% CI 0.53 to 2.23 (1cross-
sectional study (Chauchat 2017); 83 hospitals, 460 surface
samples).
• Cytarabine: RR 0.59, 95% CI 0.01 to 24.53 (1 cross-
sectional study (Chauchat 2017); 83 hospitals, 460 surface
samples).
• Gemcitabine: RR 1.13, 95% CI 0.55 to 2.33 (1 cross-
sectional study (Chauchat 2017); 83 hospitals, 460 surface
samples).
• Irinotecan: RR 0.44, 95% CI 0.03 to 6.15 (1 cross-sectional
study (Chauchat 2017); 83 hospitals, 460 surface samples).
• Docetaxel: RR 0.59, 95% CI 0.01 to 24.53 (1 cross-
sectional study (Chauchat 2017); 83 hospitals, 460 surface
samples).
• Paclitaxel: RR 0.59, 95% CI 0.01 to 24.53 (1 cross-
sectional study (Chauchat 2017); 83 hospitals, 460 surface
samples).
• Vinorelbine: RR not estimable (1 cross-sectional study
(Chauchat 2017); 83 hospitals, 460 surface samples).
• Multiple drugs (data on each drug were not available): RR
2.38, 95% CI 0.69 to 8.23 (1 cross-sectional study (Sottani
2012); 4 hospitals, 33 surface samples).
Quality of evidence: the quality of evidence is very low because of
the serious risk of bias in all the studies (downgraded by one level);
indirectness, as all the reported outcomes are surrogate outcomes
(downgraded by one level); and imprecision, as the confidence
intervals are wide (downgraded by one level).
Subgroup analysis: all the analyses stratified by the drug measured
in the samples included either uncontrolled before-after studies
or cross-sectional studies. Therefore, a subgroup analysis based
on study design is not possible. The devices used in five studies
varied (Berruyer 2015; Chauchat 2017; Janes 2015; Poupeau
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2016; Roland 2017), while one study did not report it (Sottani
2012).
Sensitivity analysis: there is also no alteration in the interpretation
of results using ICCs of 0.05, 0.01, or 0.00 (Analysis 3.4; Analysis
3.4; Analysis 3.5).
Quantity of contamination in surface samples from pharmacy
areas
Seven studies (282 hospitals, 1793 surface samples) report the
quantity of contamination with cyclophosphamide from sur-
face samples in pharmacy areas (Berruyer 2015; Chauchat 2017;
Guillemette 2014; Janes 2015; Poupeau 2016; Roland 2017;
Siderov 2010). Five are cross-sectional studies involving 279hospi-
tals using various types of CSTD (Berruyer 2015; Chauchat 2017;
Janes 2015; Poupeau 2016; Roland 2017), and two are uncon-
trolled before-after studies involving three hospitals using PhaSeal
(Guillemette 2014; Siderov 2010). The amount of cyclophos-
phamide was lower in pharmacy areas between the CSTD group
and the control group (MD −49.34 pg/cm², 95% CI −84.11 to
−14.56, I² = 0%; Analysis 1.3). There is no alteration in the in-
terpretation of results using the fixed-effect or the random-effects
model.
In addition, one interrupted time-series study (3 hospitals; 342
samples) provides data on the quantity of contamination with
cyclophosphamide from surface samples in pharmacy areas during
three, three-week phases: initial phase of no CSTD, followed by
CSTD, and then by noCSTD (Harrison 2006). Investigators took
biweekly measurements in all three phases. Between the first two
phases, the change in the slope between pre-CSTDandCSTDwas
3.9439 pg/cm² (95%CI 1.2303 to 6.6576; P = 0.01). Between the
second and third phases, the slope and level were expected to rise
again, but the change in the slope betweenCSTD and post-CSTD
withdrawal was −1.9331 pg/cm² (95% CI −5.126 to 1.2598; P
= 0.200), and the level was 14.1670 pg/cm² (SD = 10.6190).
Six studies (280 hospitals, 1749 surface samples) report the quan-
tity of contamination with ifosfamide and methotrexate from sur-
face samples in pharmacy areas (Berruyer 2015; Chauchat 2017;
Guillemette 2014; Janes 2015; Poupeau 2016; Roland 2017). Five
studies are cross-sectional studies involving 279 hospitals using
various types of CSTD (Berruyer 2015; Chauchat 2017; Janes
2015; Poupeau 2016; Roland 2017), and one study is an un-
controlled before-after study involving one hospital using PhaSeal
(Guillemette 2014). There is no evidence of difference in the
amount of ifosfamide and methotrexate in pharmacy areas be-
tween the CSTD group and the control group (MD −0.32 pg/
cm², 95% CI −6.58 to 5.94, I² = 11% and MD −3.09 pg/cm²,
95% CI −13.80 to 7.61, I² = 0%, respectively; Analysis 1.3).
There is no alteration in the interpretation of results using the
fixed-effect or the random-effects model.
Two studies (84 hospitals, 542 surface samples) report the quantity
of contamination with 5-fluorouracil (Chauchat 2017; Forges
2011). Both are cross-sectional studies. One study used variable
CSTD (Chauchat 2017), and another used Spike Swan (Forges
2011). There is no evidence of difference in the amount of 5-
fluorouracil in pharmacy areas between the CSTD group and the
control group (MD 257.87 pg/cm², 95%CI−459.65 to 975.38).
One study (83 hospitals, 493 surface samples) reports the quantity
of contamination with 5-fluorouracil, cytarabine, gemcitabine,
and irinotecan from surface samples in pharmacy areas (Chauchat
2017). This is a cross-sectional study involving 83 hospitals using
various types of CSTD (Chauchat 2017). There is no evidence
of difference in the amount of 5-fluorouracil, cytarabine, gem-
citabine, and irinotecan in pharmacy areas between the CSTD
group and the control group (5-fluorouracil: MD 256.00 pg/cm²,
95%CI−461.56 to 973.56; cytarabine:MD−0.60 pg/cm², 95%
CI −15.67 to 14.47; gemcitabine: MD−32.70 pg/cm², 95% CI
−102.43 to 37.03; and irinotecan: MD−18.27 pg/cm², 95% CI
−56.89 to 20.35; Analysis 1.3).
Quality of evidence: the quality of evidence is very low because of
the serious risk of bias in all the studies (downgraded by one level);
indirectness, as all the reported outcomes are surrogate outcomes
(downgraded by one level); and imprecision, as the confidence
intervals are wide (downgraded by one level) or there is no evidence
that the observed difference led to decreased exposure or tangible
health benefits (downgraded by one level).
Subgroup analysis: there is no evidence of subgroup differences
based on study design for the drugs for which we could perform
subgroup analyses (Analysis 2.7; Analysis 2.8; Analysis 2.9). Two
studies used PhaSeal (Guillemette 2014; Siderov 2010), while one
study used Spike Swan (Forges 2011). We could not perform tests
for subgroupdifferences as there is no comparison using twodiffer-
ent types of CSTD. Only one study reports the use of a single type
of CSTD (PhaSeal) before measuring ifosfamide and methotrex-
ate in pharmacy areas. There is no evidence of difference in the
amount of ifosfamide andmethotrexate between PhaSeal and con-
trol groups (ifosfamide: MD −2.59 pg/cm², 95% CI −26.75 to
21.57; and methotrexate: MD 10.34 pg/cm², 95% CI −34.01
to 54.69; Guillemette 2014; Analysis 2.10). All the studies that
measured the quantity of contamination in patient-care areas used
varied CSTDs, so we could not perform a subgroup analysis based
on device.
Sensitivity analysis: there is also no alteration in the interpretation
of results using ICCs of 0.05, 0.01, and0.00 (Analysis 3.7; Analysis
3.8; Analysis 3.9).
Quantity of contamination in surface samples from patient-
care areas
Five studies (279 hospitals, 1535 surface samples) report the quan-
tity of contamination from surface samples in different drugs (cy-
clophosphamide, ifosfamide, andmethotrexate) in patient-care ar-
eas (Berruyer 2015; Chauchat 2017; Janes 2015; Poupeau 2016;
Roland 2017). All studies have a cross-sectional design and used
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various types of CSTD. There is no evidence of difference in the
amount of cyclophosphamide, ifosfamide, andmethotrexate in pa-
tient-care areas between CSTD group and the control group (cy-
clophosphamide: MD −13.34 pg/cm², 95% CI −36.01 to 9.32,
I² = 0%; ifosfamide: MD 3.59 pg/cm², 95% CI −3.45 to 10.63,
I² = 0%; and methotrexate: MD 0.10 pg/cm², 95% CI −0.57 to
0.78, I² = 0%) (Analysis 1.3).
One cross-sectional study (83 hospitals, 460 surface samples) us-
ing various types of CSTD reports the quantity of contamination
with 5-fluorouracil, cytarabine, gemcitabine, and irinotecan from
surface samples in patient-care areas (Chauchat 2017). There is no
evidence of difference in the amount of 5-fluorouracil, cytarabine,
gemcitabine, and irinotecan in patient-care areas between CSTD
group and the control group (5-fluorouracil: MD−43.90 pg/cm²,
95% CI−141.51 to 53.71; cytarabine: MD−0.20 pg/cm², 95%
CI−0.79 to 0.39; gemcitabine: MD 0.47 pg/cm², 95%CI−1.77
to 2.71; and irinotecan: MD −0.05 pg/cm², 95% CI −0.15 to
0.05; Analysis 1.3).
Quality of evidence: the quality of evidence is very low because of
the serious risk of bias in all the studies (downgraded by one level);
indirectness, as all the outcomes reported are surrogate outcomes
(downgraded by one level); and imprecision, as the confidence
intervals are wide (downgraded by one level). In addition, there is
evidence of publication bias for the quantity of cyclophosphamide
in patient areas (downgraded by one level).
Subgroup analysis: all studies used various types of CSTD.
Senstivity analysis: there is also no alteration in the interpretation
of results using ICCs of 0.05, 0.01, and0.00 (Analysis 3.7; Analysis
3.8; Analysis 3.9).
Atmospheric contamination
None of the studies report atmospheric contamination.
Short-term health outcomes
None of the studies report short-term health outcomes such as
skin rashes.
Medium-term health outcomes
None of the studies report medium-term health outcomes such as
reproductive health effects (infertility or miscarriage).
Long-term health outcomes
None of the studies report long-term health outcomes such as
development of any type of cancer.
Secondary outcomes
Adverse events
None of the studies report adverse events.
Potential cost savings due to reuse of multi-dose vials
Five studies report on cost savings for drugs or the devices used
for administration or both (Chan 2016; Edwards 2013; Juhasz
2016;Mullot 2008;Ozyaman2016).None of the studies included
personnel costs (i.e. the time spent by healthcare professionals
on preparation or administration) while calculating the overall
costs. Four studies are uncontrolled before-after studies conducted
in a single hospital (Chan 2016; Edwards 2013; Mullot 2008;
Ozyaman 2016), and one is an uncontrolled before-after study
conducted in two hospitals (Juhasz 2016). Only three studies in-
cluded the costs of CSTD in the calculation of cost differences
(Chan 2016; Edwards 2013; Mullot 2008). The remaining two
studies did not (Juhasz 2016; Ozyaman 2016). The cost savings
due to CSTD are based on the potential of CSTD to maintain
drug sterility for a longer period of time. However, only one study
included the costs based on actual drug consumption (Mullot
2008); since this study also included the costs of CSTD, these
cost savings are actual cost savings. Two studies calculated the ac-
tual drugs costs in CSTD group but calculated the potential cost
savings based on the number of drug vials that would have been
used if CSTD were not used (Chan 2016; Edwards 2013). The
remaining two studies simulated cost savings based on the drug
remaining in the vials (Juhasz 2016; Ozyaman 2016). Sufficient
data for meta-analysis were available for only one study (Chan
2016). For these two reasons (variability in the calculation of costs
and the lack of sufficient data to perform the meta-analysis), we
have tabulated the data in Table 1, where we report the annual cost
savings both as originally reported and after conversion to 2017
USD using the PPP conversion rates and GDP deflators reported
in the October 2017 version of the World Economic Outlook
Database.
As noted in Table 1, there is significant variability between the
studies in terms of whether the use of CSTD results in cost savings
(the point estimates of the average potential cost savings range
between (2017) USD −642,656 and (2017) USD +221,818).
Therefore, we cannot reach any conclusion on whether the use of
CSTD in general or a particular type of CSTD results in cost sav-
ings. However, the study that reported actual cost savings reported
higher costs in the CSTD group than the control group (Mullot
2008). The quality of evidence is very low for this outcome be-
cause of the serious risk of bias in all the studies (downgraded by
one level) and the significant variability of the results between the
studies both in magnitude and direction (downgraded by two lev-
els).
24Closed-system drug-transfer devices plus safe handling of hazardous drugs versus safe handling alone for reducing exposure to infusional
hazardous drugs in healthcare staff (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Subgroup analysis
We will perform the following subgroup analyses given sufficient
data in future updates of this review; the reasons for not performing
these in this review are stated below.
• Study design (CBA studies versus other non-randomised
study designs): there are no CBA studies.
• Study design (individual versus cluster unit of analysis): all
studies are cluster studies.
• Professional role (pharmacy technician versus
chemotherapy nurse versus other healthcare staff ): no separate
data were reported for different professional roles in the two
studies that included nurses.
• Duration of possible exposure: the range of exposure to
hazardous drugs is from two weeks to seven months in the
studies that reported the presence of hazardous drugs in urine
and the duration of exposure. Thus, all the studies included
participants who had short-term exposure to hazardous drugs
and short-term follow-up.
• Control (safe handling following UK HSE standards): none
of the studies took place in the UK, and none of the studies
report whether they followed UK HSE standards.
Reporting bias
There was is evidence of reporting bias or small study effects for
the following outcomes measured in at least five studies either by
visualisation or by Egger’s test (Figure 3; Figure 4).
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Figure 3. Funnel plot of comparison: 1 Closed-system transfer device plus safe handling versus safe handling
alone, outcome: 1.2 Proportion of surfaces contaminated.
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Figure 4. Funnel plot of comparison: 1 Closed-system transfer device plus safe handling versus safe handling
alone, outcome: 1.3 Quantity of surface contamination (pg/cm²).
• Proportion of surfaces contaminated
◦ Ifosfamide (pharmacy areas): P = 0.929
◦ Methotrexate (pharmacy areas): P = 0.768
◦ Cyclophosphamide (patient-care areas): P = 0.454
◦ Ifosfamide (patient-care areas): P = 0.582
◦ Methotrexate (patient-care areas): P = 0.438
• Quantity of surface contamination
◦ Cyclophosphamide (pharmacy areas): P = 0.662
◦ Ifosfamide (pharmacy areas): P = 0.509
◦ Methotrexate (pharmacy areas): P = 0.479
◦ Ifosfamide (patient-care areas): P = 0.391
◦ Methotrexate (patient-care areas): P = 0.956
The only exceptions for this are for differences in the proportion
of surfaces contaminated with cyclophosphamide and quantity
of cyclophosphamide in patient-care areas, which are statistically
significant (P = 0.026 and P = 0.002). This is because the point
estimate of the difference between CSTD and control group is less
in the studies with the least standard error (i.e. the studies that
contributed more to the analysis) compared to the other studies
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(which contributed less to the meta-analysis), indicating potential
small-study effects.
A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Closed-system transfer device safe handling versus safe handling alone for reducing healthcare staff exposure to infusional hazardous drugs: clinical outcomes
Patient or population: healthcare staf f who handle infusional hazardous drugs
Settings: hospitals
Intervention: closed-system transfer device plus safe handling
Control: safe handling alone




Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Safe handling alone Closed-system transfer de-
vice plus safe handling
Health outcomes None of the studies report health outcomes such as skin rashes, reproduct ive health ef fects (infert ility or m iscarriage), or development of any
type of cancer
Adverse events None of the studies report this outcome.
Potential cost savings The studies used dif ferent methods of calculat ing the costs and reported results in
formats that could not be pooled via meta-analysis. There is signif icant variability
between the studies in terms of whether the use of CSTD results in cost savings
(the point est imates of the average potent ial cost savings ranged between (2017)





*Negat ive sign indicates cost savings and posit ive sign indicate increased costs due to the use of closed-system transfer device
CI: conf idence interval; CSTD: closed-system transfer device.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.






































































































































































Very low quality: we are very uncertain about the est imate.
aThe studies are at serious risk of bias (downgraded one level for risk of bias).







































































































































































D I S C U S S I O N
Summary of main results
In this systematic review, we included 23 observational studies
comparing CSTD plus safe handling versus safe handling alone.
There are no randomised controlled trials on this topic. Twenty-
one studies report one or more outcomes for this review. How-
ever, the only outcomes reported in these 21 studies are exposure,
surface contamination, and potential cost savings. None of the
studies report important health outcomes relevant for healthcare
staff exposed to infusional hazard drugs such as reduction in skin
rashes, infertility, miscarriage, or the development of any type of
cancer.
In terms of exposure, there is no evidence of differences between
CSTD plus safe handling versus safe handling alone. Decreased
exposure, as defined by the presence of one or more hazardous
drugs within the body (established via e.g. urine testing) or in the
immediate vicinity (established via surface sampling), can result in
health benefits as exposure to hazardous drugs is associated with
development of cancer, decreased fertility, congenital abnormali-
ties, miscarriages, stillbirths, and low birthweight (Connor 2014;
HSE 2017; NIOSH 2004).
There is evidence of a reduction in the proportion of samples
that were contaminated with 5-fluorouracil and in the quantity of
cyclophosphamide contamination in theCSTDplus safe handling
group versus safe handling alone in pharmacy areas. There is no
evidence of differences for any of the other drugs in proportion
of surfaces contaminated or quantity of surface contamination
in pharmacy areas. Nor is there evidence of differences in the
proportion of surfaces contaminated or the quantity of surface
contamination in patient areas.
With regards to cyclophosphamide, the surface contamination in
pharmacy areas is about 50 pg/cm² less in the intervention group
than in the control. There are multiple issues with this small differ-
ence. Firstly, the reduction compared to the baseline levels reported
in the studies is very small. Secondly, the difference in quantity of
contamination was found only for one drug in the pharmacy area
(and did not extend to patient-care areas or other drugs), that is,
the healthcare staff are still exposed to cyclophosphamide in other
areas and other hazardous drugs in pharmacy and patient-care ar-
eas. Moreover, by design, CSTDs do not protect healthcare staff
from hazardous orally administered drugs. Therefore, the health-
care staff may be exposed to hazardous oral drugs, which can lead
to the same ill effects of infusional hazardous drugs. However, haz-
ardous oral drugs were not typically reported in the studies com-
paring CSTD plus safe handling versus safe handling alone, mak-
ing it difficult to assess the potential effect of reducing some specific
infusional hazardous drugs. Because of the many hazardous drugs
to which healthcare professionals are exposed, any assessment of
surface contamination and exposure by measuring a limited num-
ber of hazardous drugs can only be an estimation of the overall ex-
posure (Connor 2006). A correlation between two outcomes does
not make one outcome a good surrogate of another (Bucher 1999;
Fleming 1996; Kim 2015; Prentice 1989; Rupp 2017a; Yudkin
2011). A reduction in the surface contamination by CSTD should
result in decreased exposure or increased health benefits for it to be
called a good surrogate outcome. To summarise, the importance
of this small reduction in cyclophosphamide in terms of reducing
overall exposure and improving health benefits is not known.
With regards to 5-fluorouracil, there is no evidence of reduction in
quantity of 5-fluorouracil despite a reduction in the proportion of
surfaces contaminated with 5-fluorouracil. There are several pos-
sible explanations for this. One possibility is that there was insuf-
ficient power to detect a reduction in quantity of 5-fluorouracil.
Even if this were the case (and there was an actual reduction in 5-
fluorouracil), the same issues arise that did for a reduction in cy-
clophosphamide: does this reduction decrease overall exposure or
does it lead to health benefits. A second possibility is that despite
a reduction in the surfaces contaminated with 5-fluorouracil, the
overall quantity of contamination with 5-fluorouracil is the same.
A third possibility is that the differences may be due to different
studies included under the outcome, which may reflect selective
outcome reporting, which may in turn indicate that there is ac-
tually no reduction in the quantity of 5-fluorouracil. In the sec-
ond and third possibilities, it is unknown whether reducing the
proportion of surfaces contaminated with 5-fluorouracil without
reducing its overall quantity leads to a decrease in overall exposure
or to an improvement in health.
All things considered, there is substantial uncertainty in whether
the addition ofCSTDto safe handlingpractices decreases exposure
or has any reduction in exposure or provides health benefits in
healthcare staff using infusional hazardous drugs.
There in significant variability in the potential cost savings. The
way that the cost savings were calculated varied significantly be-
tween the studies. A meta-analysis is not possible because of the
variability in themethods used in calculating potential cost savings
and the lack of sufficient information to perform the meta-analy-
sis. Only one study includes the costs based on actual drug con-
sumption and costs of CSTD (Mullot 2008). This study reports
higher costs. The other studies simulated cost savings, which is
likely to overestimate them. None of the studies include personnel
costs (costs involved in preparing the drugs and administration of
the drugs) when evaluating the cost savings. Overall, there is great
uncertainty in whether CSTD saves any money. Future studies
should include the total actual drug costs (based on actual drug
consumption rather than potential drug consumption), CSTD
costs, and personnel costs (costs involved in preparing the drugs
and administration of the drugs).
Based on the above observations, there is currently no evidence to
recommend the routine use of CSTD in addition to safe handling
of infusional hazardous drugs, either to attain decreased exposure,
health benefits, or financial benefits.
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Overall completeness and applicability of
evidence
Although we did not restrict the inclusion of studies based on the
hospital size, all the studies that provide information on the size of
the hospitals included only hospitals with at least 50 beds. There-
fore, the evidence is applicable only to such hospitals. Most of the
information for this review comes from pharmacy areas; therefore
the evidence is applicable only for these areas. However, patient-
care areas are equally important, as healthcare staff are also exposed
to residual hazardous drugs in these settings. Again, if studies use
surrogate measures such as surface contamination to estimate the
potential health benefit of CSTD, they should measure surface
contamination in patient-care areas in order to provide a reason-
able estimate of the health benefits of using CSTD. The healthcare
professionals in the studies that provide data were mostly pharma-
cists or pharmacy technicians. Therefore, the evidence is mainly
applicable for pharmacists and pharmacy technicians. Most of the
studies that provide information for this review evaluated the use
of PhaSeal; therefore the findings are mostly applicable to PhaSeal.
Quality of the evidence
The overall quality of evidence is very low. The major reasons for
this are as follows.
Risk of bias: all the studies are at serious risk of bias. The main
reasons for this are the use of co-interventions (for example, ad-
ditional training of staff in CSTD without the control group re-
ceiving the same amount of training in safe handling) and lack
of blinded measurement of outcomes. None of the studies report
using an independent person (blinded to the groups) for obtaining
surface samples. In addition, we assigned a ’no information’ label
for confounding bias on all the studies due to inadequate infor-
mation regarding details such as the surfaces being clean prior to
the start of the exposure. This is a particularly important prob-
lem with uncontrolled before-after studies since standard cleaning
techniques may not be sufficient to get rid of the surface contam-
ination, which might mean that the surfaces might have had sev-
eral years of exposure to contamination in the ’safe handling alone’
group, while those in the ’CSTD group plus safe handling’ group
are exposed to only a short period of exposure to contamination
(a few months typically) because of thorough cleaning prior to
start of CSTD. Even when the exposure outcome was measured
objectively, such as with a urine test where the levels can be mea-
sured using automated equipment, we found the risk of bias to be
serious.
Future studies should try to address these issues by using appro-
priate study designs that ensure that the only difference between
CSTD and control is the use of CSTD, and that an independent
person (blinded to the groups) obtains surface samples. Another
major issue is selective reporting bias, as in many instances study
authors did not report their results fully. While we acknowledge
that it is not mandatory to register observational studies, future
studies should publish a protocol prior to conducting the study
and report all the results so that it is clear that results are not re-
ported based on the observations.
Inconsistency: there is no evidence of inconsistency in the results
for exposure; however, there is major inconsistency in themethod-
ology and results of potential cost savings by CSTD. In particu-
lar, we noted major differences in the results between studies that
used actual cost savings and simulated cost savings. Future studies
should report the actual cost savings rather than simulated cost
savings.
Indirectness of evidence: because of the many hazardous drugs
to which healthcare professionals are exposed, any assessment of
exposure by measuring a limited number of hazardous drugs can
only be an estimation of the overall exposure (Connor 2006). In
addition, surface contamination can be considered a surrogate for
exposure since there is an association between the two variables
(Connor 2006).
Imprecision: as shown in the sample size calculations below, the
sample size included in this review is too small to detect a difference
in urinary exposure. In the absence of information on how much
difference in proportion of samples contaminated or in quantity
of contamination is clinically beneficial, it was not easy to assess
whether the overall sample size was sufficient to detect differences
between CSTD and control for surface contamination.
Publication bias: visualisation of funnel plots and Egger’s test
did not reveal any publication bias for most of the outcomes in
which at least five studies were included. Registration of studies
prior to conducting them allows better assessment of both selective
reporting and publication bias.
Potential biases in the review process
We followed the protocol we formulated before we started con-
ducting this Cochrane systematic review (Gurusamy 2017). The
only major deviation is the sensitivity analysis using different in-
tracluster correlation coefficients (ICCs). However, we performed
this only to assess the reason for the differences in the conclusions
reached by us and a number the study authors; in particular, we
did not use these post hoc sensitivity analyses to make any infer-
ences about the effect of CSTD.
While we have minimised the errors in study selection and data
extraction by independent, duplicate performance of these pro-
cesses, we may have missed studies that do not mention CSTD in
the title or abstract. It is impractical to review the full text of all
references (we identified 7321 unique references using our search
strategy). In this regard, we followed our protocol of screening the
title and abstract and obtaining full texts for references considered
relevant based on the full text. Besides, these studies (which do
not mention CSTD in the title or abstract) are likely to show no
evidence of benefit of CSTD (the probable reason for not men-
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tioning CSTD in the title or abstract); therefore, our conclusions
are unlikely to change.
None of the studies reported an ICC. Therefore, we used the value
of 0.10 decided a priori based on studies about implementation
research (Campbell 2001). The results were robust in a sensitivity
analysis using 0.05 for the ICC (i.e. half the correlation noted
in similar studies) for most analyses; therefore, our conclusions
would probably not change even if the studies had reported the
intracluster correlation. However, we recommend that study au-
thors report intracluster correlations in the future to enable accu-
rate estimation of their results.
Agreements and disagreements with other
studies or reviews
This is the first systematic review on the topic. We disagree with
the study authors who concluded that routine CSTD use is ben-
eficial (Edwards 2013; Hama 2012; Juhasz 2016; Miyake 2013;
Ozyaman 2016; Sessink 2011; Sessink 2013; Siderov 2010; Simon
2016; Wick 2003; Yoshida 2011). Ignoring the design effect by
not adjusting the effect estimates for intracluster correlation can
lead to an underestimation of random errors (Killip 2004); conse-
quently this could lead to erroneous conclusions. Ignoring the de-
sign effect by the study authors, the risk of bias in the studies, and
the excessive importance given to unvalidated surrogate outcomes
by the study authors are the major differences in the conclusions
between this systematic review and the primary research studies.
We also disagree with any guidelines or recommendations that
CSTD should be used routinely whenever possible (HSE 2017;
NIOSH 2004; USP 2017), for the same reasons we disagree with
the study authors who concluded that routine CSTD use is ben-
eficial.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is currently no evidence to support or refute the routine use
of closed-system drug-transfer devices in addition to safe handling
of infusional hazardous drugs, as there is currently no evidence
of differences in exposure or financial benefits between CSTD
plus safe handling versus safe handling alone (very low-quality
evidence). None of the studies report health benefits.
Implications for research
Future studies should be designed in such a way as to decrease the
risk of bias.
Study design
Well-designed multicentre randomised controlled trials may be
feasible if the exposure, as measured by urine samples, is high
(please see sample size calculations below). The next best study
design is interrupted time-series, which is likely to provide a better
estimate than uncontrolled before-after studies or cross-sectional
studies. In all types of study designs, investigators should take steps
to ensure that there are no other differences between CSTD and
control groups, so that they can obtain a reasonable estimate of
decrease in exposure and the health benefits of using CSTD. This
includes measures such as proper cleaning of the surfaces prior
to exposure of both the intervention and control groups (i.e. all
surfaces should be cleaned and samples taken to ensure that they
are clean, followed by exposure to an equivalent period of time in
the safe handling alone group as in the CSTD plus safe handling
group), so that there is no residual contamination. Likewise, staff
in both groups should receive an equal period of training forCSTD
plus safe handling and safe handling alone of infusional hazardous
drugs. This will ensure that the effect observed is the true effect
due to CSTD. Other information of interest includes the annual
drug use within the centre, description of the tasks performed by
the staff, and the safe handling practices used, so that it is possible
to estimate the effect of CSTD in different situations. Studies
should register their protocol prospectively, for example in journal
publications, ClinicalTrials.gov, or scientific repositories such as
zenodo.org.
Population
Staff exposed to infusional hazardous drugs.
Study arms
Intervention: CSTD plus safe handling.
Control: safe handling alone or other measures such as central
priming of intravenous tubes, cleaning of vials, cleaning of sur-
faces, management of patient excreta and storage in addition to
safe handling (multi-arm randomised controlled trials or factorial
trial design).
Outcomes
Primary outcome: exposure to an appropriate selection of haz-
ardous drugs used in the hospitals.
Secondary outcomes: health benefits and cost-effectiveness.
In the future, studies using exposure as an outcome shouldmeasure
exposure to a relevant selection of hazardous drugs in order to
provide a reasonable estimate of the health benefits of usingCSTD.
Surface contamination should be considered less important than
exposure. This is because the staff are exposed to other unmeasured
hazardous drugs and contamination in patient-care areas. Using
surface contamination as the primary outcome has the potential
to lead to complacency in handling drugs.
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Sample size calculations
The baseline risk of cancers in people exposed to hazardous drugs
is 0.3% (Ratner 2010). Using an alpha error of 5%, power of
80%, and a relative risk reduction of 20%, the unadjusted sample
size required is 234,830. Using an ICC of 0.10 and the median
cluster size of 13 observed in the studies that report on exposure,
the sample size adjusted for clustering is 516,626.
The baseline risk of congenital anomalies in women who were
exposed to hazardous drugs is 0.1% to 6.0% (Connor 2014).
Using the median baseline risk of congenital anomalies and the
same parameters as for the previous sample size calculation, the
unadjusted sample size required is 30,078 and the adjusted sample
size is 66,172.
The risk of stillbirths, miscarriages, and tubal pregnancies in
women exposed to hazardous drugs is 0.1% to 25.9%, depending
on the methods used to calculate the risk (Connor 2014). This
results in an unadjusted sample size of 31,474 and an adjusted
sample size of 69,243 using the median baseline risk of 2.2% and
the same parameters of above.
The true incidence of acute ill health effects due to exposure to
infusional hazardous drugs is not known. Using an estimate of
5% of people using safe handling practices with the remaining
parameters remaining the same as above, an unadjusted sample
size of 13,492 and adjusted sample size of 29,682 is required.
None of these outcomes can be explored in randomised controlled
settings because these sample sizes are impractical, even if the ICC
were much smaller than 0.10. About 77% of people using safe
handling alone had hazardous drugs in their urine, based on the
median baseline risk in the studies included in this systematic re-
view. Using a relative risk reduction of 44% (median risk reduc-
tion in the three studies in which one or more people in the safe
handling group had hazardous drugs in the urine), an alpha error
of 5%, power of 80%, an ICC of 0.10, and a cluster size of 13,
the unadjusted sample size required is 66 and the adjusted sample
size is 145. This can be achieved, but requires multicentre studies.
However, other studies have indicated that none of the healthcare
staff had positive urine samples (Poupeau 2017; Sottani 2012),
which may reflect high quality safety handling practices or dif-
ferences in methodology used to collect urine (spot urine sample
versus 24-hour urine sample). If the rates of urinary exposure are
low, then it will be difficult to conduct a randomised controlled
trial, and interrupted time-series may be a good alternative.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Berruyer 2015
Methods Cross-sectional study; cluster study
Participants Country: Canada
Number of clusters: 36
Number excluded: 1 (2.8%)
Reason for exclusion: one hospital did not provide reply to the CSTD status
Number included: 35
Chemotherapy agents tested for contamination: cyclophosphamide, ifosfamide, and
methotrexate
Professional role: pharmacy technician/pharmacist
Size of the hospitals/wards: at least 50 beds
Interventions Group 1: CSTD + standard care (variable) (N = 7)
Group 2: standard care (variable including removal of outer packaging and cleaned vials
after receipt in some hospitals) (N = 28)
Outcomes Outcomes reported: surface contamination
Notes Authors provided additional information.
Risk of bias
Bias Authors’ judgement Support for judgement
Confounding bias Unclear risk Risk of bias: no information
Comment: no information to judge whether the
confounding factors were balanced across groups
Selection bias Unclear risk Risk of bias: moderate
Comment: the participating centres may have
done so based on their pharmacological practices
Bias in classification of interventions Low risk Risk of bias: low
Comment: the intervention and control were well
defined
Bias due to deviations from intended inter-
ventions
Unclear risk Risk of bias: no information
Comment: no information to judge whether the
co-interventions were similar across the groups
Bias due to missing data Unclear risk Risk of bias: no information
Comment: insufficient information to judge
whether there was bias due tomissing data (i.e. the
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Berruyer 2015 (Continued)
hospital which did not reply about CSTD status
may have done so because of the intervention or
the outcome)
Bias in measurement of outcomes High risk Risk of bias: serious
Comment: the outcome assessors do not seem to
be blinded to the groups
Bias in selection of the reported result High risk Risk of bias: serious
Comment: only selected results were reported
Chan 2016
Methods Uncontrolled before-after cohort study; cluster study
Participants Country: Malaysia
Number of clusters: 2
Number excluded: 0 (0%)
Number included: 2
Chemotherapy agents tested for contamination: not measured
Professional role: pharmacists or pharmacy technicians
Size of the hospitals/wards: 852 beds
Interventions Group 1: CSTD + standard care (PhaSeal) (N = 1)
Group 2: Standard care (not stated) (N = 1)
Outcomes Outcomes reported: potential cost savings
Notes Authors provided additional information.
Risk of bias
Bias Authors’ judgement Support for judgement
Confounding bias Unclear risk Risk of bias: no information
Comment: no information to judge
whether the confounding factors were bal-
anced across groups
Selection bias Low risk Risk of bias: low
Comment: the research was performed in
the same centre
Bias in classification of interventions Low risk Risk of bias: low
Comment: the intervention and control
were well defined
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Chan 2016 (Continued)
Bias due to deviations from intended inter-
ventions
Unclear risk Risk of bias: no information
Comment: no information to judge
whether the co-interventions were similar
across the groups
Bias due to missing data Low risk Risk of bias: low
Comment: all samples were probably in-
cluded in the analysis
Bias in measurement of outcomes High risk Risk of bias: serious
Comment: the outcome assessors do not
seem to be blinded to the groups
Bias in selection of the reported result High risk Risk of bias: serious
Comment: actual savings based on the
reuse of the drug were not reported despite
being probably collected
Chauchat 2017
Methods Cross-sectional study; cluster study
Participants Country: Canada
Number of clusters: 83
Number excluded: 0 (0%)
Number included: 83
Chemotherapy agents tested for contamination: cyclophosphamide, ifosfamide,
methotrexate, 5-fluorouracil, cytarabine, gemcitabine, irinotecan, and other drugs
Professional role: pharmacy technician/pharmacist
Size of the hospitals/wards: > 50 beds
Interventions Group 1: CSTD + standard care (variable) (N = 31)
Group 2: standard care (not stated) (N = 52)
Outcomes Outcomes reported: surface contamination
Notes Unpublished data
Risk of bias
Bias Authors’ judgement Support for judgement
Confounding bias Unclear risk Risk of bias: no information
Comment: no information to judge whether the
confounding factors were balanced across groups
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Chauchat 2017 (Continued)
Selection bias Unclear risk Risk of bias: moderate
Comment: the participating centres may have
done so based on their pharmacological practices
Bias in classification of interventions Low risk Risk of bias: low
Comment: the intervention and control were well
defined
Bias due to deviations from intended inter-
ventions
Unclear risk Risk of bias: no information
Comment: no information to judge whether the
co-interventions were similar across the groups
Bias due to missing data Low risk Risk of bias: low
Comment: all samples were included in the anal-
ysis
Bias in measurement of outcomes High risk Risk of bias: serious
Comment: the outcome assessors do not seem to
be blinded to the groups
Bias in selection of the reported result High risk Risk of bias: serious
Comment: results were not reported fully
Edwards 2013
Methods Uncontrolled before-after cohort study; cluster study
Participants Country: USA
Number of clusters: 2
Number excluded: 0 (0%)
Number included: 2
Chemotherapy agents tested for contamination: not measured
Professional role: pharmacy (not clear whether pharmacist or pharmacy technician)
Size of the hospitals/wards: 335 beds
Interventions Group 1: CSTD + standard care (PhaSeal) (N = 1)
Group 2: standard care (not stated) (N = 1)
Outcomes Outcomes reported: potential cost savings
Notes Authors provided additional information.
Risk of bias
Bias Authors’ judgement Support for judgement
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Edwards 2013 (Continued)
Confounding bias Unclear risk Risk of bias: no information
Comment: no information to judge
whether the confounding factors were bal-
anced across groups
Selection bias Low risk Risk of bias: low
Comment: the research was performed in
the same centre
Bias in classification of interventions Low risk Risk of bias: low
Comment: the intervention and control
were well defined
Bias due to deviations from intended inter-
ventions
Unclear risk Risk of bias: no information
Comment: no information to judge
whether the co-interventions were similar
across the groups
Bias due to missing data Low risk Risk of bias: low
Comment: all samples were probably in-
cluded in the analysis
Bias in measurement of outcomes High risk Risk of bias: serious
Comment: the outcome assessors do not
seem to be blinded to the groups
Bias in selection of the reported result High risk Risk of bias: serious
Comment: actual savings based on the
reuse of the drug were not reported despite
being probably collected
Forges 2011
Methods Cross-sectional study; cluster study
Participants Country: France
Number of clusters: 2
Number excluded: not stated
Number included: 2
Chemotherapy agents tested for contamination: 5-fluorouracil
Professional role: pharmacy technician
Size of the hospitals/wards: not stated
Interventions Group 1: CSTD + standard care (Spike Swan) (N = 1)
Group 2: standard care (isolators, gloves, and daily washing) (N = 1)
Outcomes Outcomes reported: surface contamination
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Bias Authors’ judgement Support for judgement
Confounding bias Unclear risk Risk of bias: no information
Comment: no information to judge whether the
confounding factors were balanced across groups
Selection bias Low risk Risk of bias: low
Comment: the isolators were all in the same centre
and some preparations were made with CSTD
while others were not made with CSTD
Bias in classification of interventions Low risk Risk of bias: low
Comment: the intervention and control were well
defined
Bias due to deviations from intended inter-
ventions
High risk Risk of bias: serious
Comment: only the intervention group received
additional training and supervision
Bias due to missing data Unclear risk Risk of bias: no information
Comment: insufficient information to judge
whether there was bias due to missing data
Bias in measurement of outcomes High risk Risk of bias: serious
Comment: the outcome assessors do not seem to
be blinded to the groups
Bias in selection of the reported result Low risk Risk of bias: low
Comment: the authors appear to have reported all
the results
Guillemette 2014
Methods Uncontrolled before-after cohort study; cluster study
Participants Country: Canada
Number of clusters: 2
Number excluded: 0 (0%)
Number included: 2
Chemotherapy agents tested for contamination: cyclophosphamide, ifosfamide, and
methotrexate
Professional role: pharmacy technician
Size of the hospitals/wards: > 500 beds
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Guillemette 2014 (Continued)
Interventions Group 1: CSTD + standard care (PhaSeal) (N = 1)
Group 2: standard care (biological safety cabinets ) (N = 1)
Outcomes Outcomes reported: surface contamination
Notes Authors provided additional information
Risk of bias
Bias Authors’ judgement Support for judgement
Confounding bias Unclear risk Risk of bias: no information
Comment: no information to judge
whether the confounding factors were bal-
anced across groups
Selection bias High risk Risk of bias: serious
Comment: although the research was per-
formed in the same centre, different sites
were chosen for sampling from the inter-
vention and control
Bias in classification of interventions Low risk Risk of bias: low
Comment: the intervention and control
were well defined
Bias due to deviations from intended inter-
ventions
High risk Risk of bias: serious
Comment: the technicians received addi-
tional training prior to the intervention
Bias due to missing data Low risk Risk of bias: low
Comment: all samples were included in the
analysis
Bias in measurement of outcomes High risk Risk of bias: serious
Comment: the outcome assessors do not
seem to be blinded to the groups
Bias in selection of the reported result High risk Risk of bias: serious
Comment: only selected results were re-
ported
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Hama 2012
Methods Uncontrolled before-after cohort study; cluster study
Participants Country: Japan
Number of clusters: 2
Number excluded: 0 (0%)
Number included: 2
Chemotherapy agents tested for contamination: cyclophosphamide
Professional role: pharmacists
Size of the hospitals/wards: > 150 patients per day
Interventions Group 1: CSTD + standard care (PhaSeal) (N = 1)
Group 2: standard care (personal protective equipment) (N = 1)
Outcomes None of the outcomes of interest were reported.
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Confounding bias Unclear risk Risk of bias: no information
Comment: no information to judge
whether the confounding factors were bal-
anced across groups
Selection bias Low risk Risk of bias: low
Comment: the research was performed in
the same centre
Bias in classification of interventions Low risk Risk of bias: low
Comment: the intervention and control
were well defined
Bias due to deviations from intended inter-
ventions
Unclear risk Risk of bias: no information
Comment: no information to judge
whether the co-interventions were similar
across the groups
Bias due to missing data Unclear risk Risk of bias: no information
Comment: insufficient information to
judge whether there was bias due to miss-
ing data
Bias in measurement of outcomes High risk Risk of bias: serious
Comment: the outcome assessors do not
seem to be blinded to the groups
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Hama 2012 (Continued)
Bias in selection of the reported result High risk Risk of bias: serious
Comment: only selected results were re-
ported, but even these were not reported
in a format fromwhich inferences could be
made
Harrison 2006
Methods interrupted time-series; cluster study
Participants Country: USA
Number of clusters: 6
Number excluded: 0 (0%)
Number included: 6
Chemotherapy agents tested for contamination: cyclophosphamide, fluorouracil
Professional role: pharmacists
Size of the hospitals/wards: not stated
Interventions Group 1: CSTD + standard care (PhaSeal) (N = 3)
Group 2: standard care (biological safety cabinets, latex rubber chemoprotective gloves,
disposable gowns, and aseptic and negative-pressure mixing techniques) (N = 3)
Outcomes Outcomes reported: surface contamination
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Confounding bias Unclear risk Risk of bias: no information
Comment: no information to judge whether the
confounding factorswere balanced across groups
Selection bias Low risk Risk of bias: low
Comment: the research was performed in the
same centre
Bias in classification of interventions Low risk Risk of bias: low
Comment: the intervention and control were
well defined
Bias due to deviations from intended inter-
ventions
Unclear risk Risk of bias: no information
Comment: no information to judge whether the
co-interventions were similar across the groups
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Harrison 2006 (Continued)
Bias due to missing data Unclear risk Risk of bias: no information
Comment: insufficient information to judge
whether there was bias due to missing data
Bias in measurement of outcomes High risk Risk of bias: serious
Comment: the outcome assessors do not seem
to be blinded to the groups
Bias in selection of the reported result High risk Risk of bias: serious
Comment: the authors have not reported the
results fully and this seems to be dependent upon
the results
Janes 2015
Methods Cross-sectional study; cluster study
Participants Country: Canada
Number of clusters: 51
Number excluded: 2 (3.9%)
Reason for exclusion: 2 hospitals did not provide reply to the CSTD status
Number included: 49
Chemotherapy agents tested for contamination: cyclophosphamide, ifosfamide, and
methotrexate
Professional role: pharmacy technician/pharmacist
Size of the hospitals/wards: at least 50 beds
Interventions Group 1: CSTD + standard care (variable) (N = 12)
Group 2: standard care (variable including removal of outer packaging and cleaned vials
after receipt in some hospitals) (N = 37)
Outcomes Outcomes reported: surface contamination
Notes Authors provided additional information.
Risk of bias
Bias Authors’ judgement Support for judgement
Confounding bias Unclear risk Risk of bias: no information
Comment: no information to judge whether the
confounding factors were balanced across groups
Selection bias Unclear risk Risk of bias: moderate
Comment: the participating centres may have
done so based on their pharmacological practices
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Janes 2015 (Continued)
Bias in classification of interventions Low risk Risk of bias: low
Comment: the intervention and control were well
defined
Bias due to deviations from intended inter-
ventions
Unclear risk Risk of bias: no information
Comment: no information to judge whether the
co-interventions were similar across the groups
Bias due to missing data Unclear risk Risk of bias: no information
Comment: insufficient information to judge
whether there was bias due tomissing data (i.e. the
hospitals which did not reply about CSTD status
may have done so because of the intervention or
the outcome)
Bias in measurement of outcomes High risk Risk of bias: serious
Comment: the outcome assessors do not seem to
be blinded to the groups
Bias in selection of the reported result High risk Risk of bias: serious
Comment: only selected results were reported
Juhasz 2016
Methods Uncontrolled before-after cohort study; cluster study
Participants Country: Hungary
Number of clusters: 4
Number excluded: 0 (0%)
Number included: 4
Chemotherapy agents tested for contamination: not measured
Professional role: pharmacy (not clear whether pharmacist or pharmacy technician)
Size of the hospitals/wards: 335 beds
Interventions Group 1: CSTD + standard care (Tevadaptor) (N = 2)
Group 2: standard care (not stated) (N = 2)
Outcomes Outcomes reported: potential cost savings
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Confounding bias Unclear risk Risk of bias: no information
Comment: no information to judge
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Juhasz 2016 (Continued)
whether the confounding factors were bal-
anced across groups
Selection bias Low risk Risk of bias: low
Comment: the research was performed in
the same centres
Bias in classification of interventions Low risk Risk of bias: low
Comment: the intervention and control
were well defined
Bias due to deviations from intended inter-
ventions
Unclear risk Risk of bias: no information
Comment: no information to judge
whether the co-interventions were similar
across the groups
Bias due to missing data Low risk Risk of bias: low
Comment: all samples were probably in-
cluded in the analysis
Bias in measurement of outcomes High risk Risk of bias: serious
Comment: the outcome assessors do not
seem to be blinded to the groups
Bias in selection of the reported result High risk Risk of bias: serious
Comment: actual savings based on the
reuse of the drug were not reported despite
being probably collected
Miyake 2013
Methods Uncontrolled before-after cohort study; cluster study
Participants Country: Japan
Number of clusters: 2
Number excluded: 0 (0%)
Number included: 2
Chemotherapy agents tested for contamination: cyclophosphamide
Professional role: pharmacist
Size of the hospitals/wards: 655 beds
Interventions Group 1: CSTD + standard care (PhaSeal) (N = 1)
Group 2: standard care (not stated) (N = 1)
Outcomes Outcomes reported: exposure and surface contamination
Notes -
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Miyake 2013 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Confounding bias Unclear risk Risk of bias: no information
Comment: no information to judge
whether the confounding factors were bal-
anced across groups
Selection bias Low risk Risk of bias: low
Comment: the research was performed in
the same centre
Bias in classification of interventions Low risk Risk of bias: low
Comment: the intervention and control
were well defined
Bias due to deviations from intended inter-
ventions
High risk Risk of bias: serious
Comment: the pharmacists received train-
ing prior to use of CSTD. No such training
was provided in the control group
Bias due to missing data Low risk Risk of bias: low
Comment: all samples were included in the
analysis
Bias in measurement of outcomes High risk Risk of bias: serious
Comment: the outcome assessors do not
seem to be blinded to the groups
Bias in selection of the reported result Low risk Risk of bias: low
Comment: all results seem to be reported
Mullot 2008
Methods Uncontrolled before-after cohort study; cluster study
Participants Country: France
Number of clusters: 2
Number excluded: 0 (0%)
Number included: 2
Chemotherapy agents tested for contamination: not measured
Professional role: pharmacist, pharmacy technician, nurse
Size of the hospitals/wards: not stated, but about 150 preparations per day
Interventions Group 1: CSTD + standard care (PhaSeal/Tevadaptor) (N = 1)
Group 2: standard care (hood with laminar flow, isolators, neoprene gloves, air intake
with standard needles (no spike use)) (N = 1)
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Mullot 2008 (Continued)
Outcomes Outcomes reported: potential cost savings
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Confounding bias Unclear risk Risk of bias: no information
Comment: no information to judge
whether the confounding factors were bal-
anced across groups
Selection bias Low risk Risk of bias: low
Comment: the research was performed in
the same centre
Bias in classification of interventions Low risk Risk of bias: low
Comment: the intervention and control
were well defined
Bias due to deviations from intended inter-
ventions
High risk Risk of bias: serious
Comment: the personnel received training
prior to use of CSTD.No such trainingwas
provided in the control group
Bias due to missing data Low risk Risk of bias: low
Comment: all samples were probably in-
cluded in the analysis
Bias in measurement of outcomes High risk Risk of bias: serious
Comment: the outcome assessors do not
seem to be blinded to the groups
Bias in selection of the reported result High risk Risk of bias: serious
Comment: results were not reported in a
format that could be meta-analysed
Ozyaman 2016
Methods Uncontrolled before-after cohort study; cluster study
Participants Country: Turkey
Number of clusters: 2
Number excluded: 0 (0%)
Number included: 2
Chemotherapy agents tested for contamination: not measured
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Ozyaman 2016 (Continued)
Professional role: pharmacy (not clear whether pharmacist or pharmacy technician)
Size of the hospitals/wards: not stated
Interventions Group 1: CSTD + standard care (PhaSeal) (N = 1)
Group 2: standard care (not stated) (N = 1)
Outcomes Outcomes reported: potential cost savings
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Confounding bias Unclear risk Risk of bias: no information
Comment: no information to judge
whether the confounding factors were bal-
anced across groups
Selection bias Low risk Risk of bias: low
Comment: the research was performed in
the same centre
Bias in classification of interventions Low risk Risk of bias: low
Comment: the intervention and control
were well defined
Bias due to deviations from intended inter-
ventions
Unclear risk Risk of bias: no information
Comment: no information to judge
whether the co-interventions were similar
across the groups
Bias due to missing data Low risk Risk of bias: low
Comment: all samples were probably in-
cluded in the analysis
Bias in measurement of outcomes High risk Risk of bias: serious
Comment: the outcome assessors do not
seem to be blinded to the groups
Bias in selection of the reported result High risk Risk of bias: serious
Comment: actual savings based on the
reuse of the drug were not reported despite
being probably collected
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Poupeau 2016
Methods Cross-sectional study; cluster study
Participants Country: Canada
Number of clusters: 48
Number excluded: 2 (4.2%)
Reason for exclusion: Two hospitals did not provide reply to the CSTD status
Number included: 46
Chemotherapy agents tested for contamination: cyclophosphamide, ifosfamide, and
methotrexate
Professional role: pharmacy technician/pharmacist
Size of the hospitals/wards: at least 50 beds
Interventions Group 1: CSTD + standard care (variable) (N = 12)
Group 2: standard care (variable including removal of outer packaging and cleaned vials
after receipt in some hospitals) (N = 34)
Outcomes Outcomes reported: surface contamination
Notes Authors provided additional information
Risk of bias
Bias Authors’ judgement Support for judgement
Confounding bias Unclear risk Risk of bias: no information
Comment: no information to judge whether the
confounding factors were balanced across groups
Selection bias Unclear risk Risk of bias: moderate
Comment: the participating centres may have
done so based on their pharmacological practices
Bias in classification of interventions Low risk Risk of bias: low
Comment: the intervention and control were well
defined
Bias due to deviations from intended inter-
ventions
Unclear risk Risk of bias: no information
Comment: no information to judge whether the
co-interventions were similar across the groups
Bias due to missing data Unclear risk Risk of bias: no information
Comment: insufficient information to judge
whether there was bias due tomissing data (i.e. the
hospitals which did not reply about CSTD status
may have done so because of the intervention or
the outcome)
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Poupeau 2016 (Continued)
Bias in measurement of outcomes High risk Risk of bias: serious
Comment: the outcome assessors do not seem to
be blinded to the groups
Bias in selection of the reported result High risk Risk of bias: serious
Comment: only selected results were reported
Roland 2017
Methods Cross-sectional study; cluster study
Participants Country: Canada
Number of clusters: 66
Number excluded: 0 (0%)
Number included: 66
Chemotherapy agents tested for contamination: cyclophosphamide, ifosfamide, and
methotrexate
Professional role: pharmacy technician/pharmacist
Size of the hospitals/wards: at least 50 beds
Interventions Group 1: CSTD + standard care (variable) (N = 23)
Group 2: standard care (variable including removal of outer packaging and cleaned vials
after receipt in some hospitals) (N = 43)
Outcomes Outcomes reported: surface contamination
Notes Authors provided additional information.
Risk of bias
Bias Authors’ judgement Support for judgement
Confounding bias Unclear risk Risk of bias: no information
Comment: no information to judge whether the
confounding factors were balanced across groups
Selection bias Unclear risk Risk of bias: moderate
Comment: the participating centres may have
done so based on their pharmacological practices
Bias in classification of interventions Low risk Risk of bias: low
Comment: the intervention and control were well
defined
Bias due to deviations from intended inter-
ventions
Unclear risk Risk of bias: no information
Comment: no information to judge whether the
co-interventions were similar across the groups
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Roland 2017 (Continued)
Bias due to missing data Low risk Risk of bias: low
Comment: all samples were included in the anal-
ysis
Bias in measurement of outcomes High risk Risk of bias: serious
Comment: the outcome assessors do not seem to
be blinded to the groups
Bias in selection of the reported result High risk Risk of bias: serious
Comment: only selected results were reported
Sessink 2011
Methods Uncontrolled before-after cohort study; cluster study
Participants Country: USA
Number of clusters: 44
Number excluded: 0 (0%)
Number included: 44
Chemotherapy agents tested for contamination: cyclophosphamide, ifosfamide, and 5-
fluorouracil
Professional role: pharmacist
Size of the hospitals/wards: not stated
Interventions Group 1: CSTD + standard care (PhaSeal) (N = 22)
Group 2: standard care (class II BSCs, protective gloves, disposable gowns, and aseptic
and negative-pressure mixing techniques using needle syringes) (N = 22)
Outcomes Outcomes reported: surface contamination
Notes Authors provided additional information.
Risk of bias
Bias Authors’ judgement Support for judgement
Confounding bias Unclear risk Risk of bias: no information
Comment: no information to judge
whether the confounding factors were bal-
anced across groups
Selection bias Unclear risk Risk of bias: moderate
Comment: the participating centres were
probably selected based on their pharma-
cological practices
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Sessink 2011 (Continued)
Bias in classification of interventions Low risk Risk of bias: low
Comment: the intervention and control
were well defined
Bias due to deviations from intended inter-
ventions
Unclear risk Risk of bias: no information
Comment: no information to judge
whether the co-interventions were similar
across the groups
Bias due to missing data Low risk Risk of bias: low
Comment: all samples were included in the
analysis
Bias in measurement of outcomes High risk Risk of bias: serious
Comment: the outcome assessors do not
seem to be blinded to the groups
Bias in selection of the reported result High risk Risk of bias: serious
Comment: only selected results were re-
ported and none could be used for the sys-
tematic review
Sessink 2013
Methods Uncontrolled before-after cohort study; cluster study
Participants Country: USA
Number of clusters: 60
Number excluded: 0 (0%)
Number included: 60
Chemotherapy agents tested for contamination: cyclophosphamide
Professional role: pharmacist
Size of the hospitals/wards: not stated
Interventions Group 1: CSTD + standard care (PhaSeal) (N = 30)
Group 2: standard care (not stated) (N = 30)
Outcomes Outcomes reported: surface contamination
Notes Authors provided additional information.
Risk of bias
Bias Authors’ judgement Support for judgement
Confounding bias Unclear risk Risk of bias: no information
Comment: no information to judge
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Sessink 2013 (Continued)
whether the confounding factors were bal-
anced across groups
Selection bias Unclear risk Risk of bias: moderate
Comment: the participating centres were
probably selected based on their pharma-
cological practices
Bias in classification of interventions Low risk Risk of bias: low
Comment: the intervention and control
were well defined
Bias due to deviations from intended inter-
ventions
Unclear risk Risk of bias: no information
Comment: no information to judge
whether the co-interventions were similar
across the groups
Bias due to missing data Low risk Risk of bias: low
Comment: all samples were included in the
analysis
Bias in measurement of outcomes High risk Risk of bias: serious
Comment: the outcome assessors do not
seem to be blinded to the groups
Bias in selection of the reported result High risk Risk of bias: serious
Comment: only selected results were re-
ported and none could be used for the sys-
tematic review
Siderov 2010
Methods Uncontrolled before-after cohort study; cluster study
Participants Country: Australia
Number of clusters: 4
Number excluded: 0 (0%)
Number included: 4
Chemotherapy agents tested for contamination: cyclophosphamide
Professional role: pharmacist
Size of the hospitals/wards: not stated
Interventions Group 1: CSTD + standard care (PhaSeal) (N = 2)
Group 2: standard care (not stated) (N = 2)
Outcomes Outcomes reported: surface contamination
Notes -
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Siderov 2010 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Confounding bias Unclear risk Risk of bias: no information
Comment: no information to judge
whether the confounding factors were bal-
anced across groups
Selection bias Low risk Risk of bias: low
Comment: the research was performed in
the same centre
Bias in classification of interventions Low risk Risk of bias: low
Comment: the intervention and control
were well defined
Bias due to deviations from intended inter-
ventions
Unclear risk Risk of bias: no information
Comment: no information to judge
whether the co-interventions were similar
across the groups
Bias due to missing data Low risk Risk of bias: low
Comment: all samples were included in the
analysis
Bias in measurement of outcomes High risk Risk of bias: serious
Comment: the outcome assessors do not
seem to be blinded to the groups
Bias in selection of the reported result Low risk Risk of bias: low
Comment: all results seem to be reported
Simon 2016
Methods Cross-sectional study; cluster study
Participants Country: France
Number of clusters: 2
Number excluded: 0 (0%)
Number included: 2
Chemotherapy agents tested for contamination: cyclophosphamide; cytarabine; cy-
tarabine; dacarbazine; doxorubicin; fluorouracil; ganciclovir; gemcitabine; ifosfamide;
irinotecan
Professional role: pharmacist
Size of the hospitals/wards: not stated
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Simon 2016 (Continued)
Interventions Group 1: CSTD + standard care (PhaSeal) (N = 1)
Group 2: standard care (isolators and personal protective equipment (gloves, sterile
drapes, compresses)) (N = 1)
Outcomes Outcomes reported: surface contamination
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Confounding bias Unclear risk Risk of bias: no information
Comment: no information to judge whether the
confounding factors were balanced across groups
Selection bias Low risk Risk of bias: low
Comment: the research was performed in 2 isola-
tors in the same centre: in 1 isolator, CSTD was
used; in the other it was not
Bias in classification of interventions Low risk Risk of bias: low
Comment: the intervention and control were well
defined
Bias due to deviations from intended inter-
ventions
High risk Risk of bias: serious
Comment: the pharmacists received received
training prior to use of CSTD. No such training
was provided in the control group
Bias due to missing data Low risk Risk of bias: low
Comment: almost all samples were included in
the analysis
Bias in measurement of outcomes High risk Risk of bias: serious
Comment: the outcome assessors do not seem to
be blinded to the groups
Bias in selection of the reported result High risk Risk of bias: serious
Comment: only selected results were reported and
none could be used for the systematic review
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Sottani 2012
Methods Cross-sectional study; cluster study
Participants Country: Italy
Number of clusters: 4
Number excluded: 0 (0%)
Number included: 4
Chemotherapy agents tested for contamination: cyclophosphamide, ifosfamide, and
gemcitabine
Professional role: pharmacy technician
Size of the hospitals/wards: not stated
Interventions Group 1: CSTD + standard care (not stated) (N = 3)
Group 2: standard care (not stated) (N = 1)
Outcomes Outcomes reported: exposure and surface contamination
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Confounding bias Unclear risk Risk of bias: no information
Comment: no information to judge whether the
confounding factors were balanced across groups
Selection bias Unclear risk Risk of bias: moderate
Comment: the participating centres were proba-
bly selected based on their pharmacological prac-
tices
Bias in classification of interventions Low risk Risk of bias: low
Comment: the intervention and control were well
defined
Bias due to deviations from intended inter-
ventions
Unclear risk Risk of bias: no information
Comment: no information to judge whether the
co-interventions were similar across the groups
Bias due to missing data Low risk Risk of bias: low
Comment: all samples were included in the anal-
ysis
Bias in measurement of outcomes High risk Risk of bias: serious
Comment: the outcome assessors do not seem to
be blinded to the groups
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Sottani 2012 (Continued)
Bias in selection of the reported result Low risk Risk of bias: low
Comment: all results seem to be reported
Wick 2003
Methods Uncontrolled before-after cohort study; cluster study
Participants Country: USA
Number of clusters: 2
Number excluded: 0 (0%)
Number included: 2
Chemotherapy agents tested for contamination: cyclophosphamide and ifosfamide
Professional role: pharmacist, pharmacy technician, nurse
Size of the hospitals/wards: not stated
Interventions Group 1: CSTD + standard care (PhaSeal) (N = 1)
Group 2: standard care (not stated) (N = 1)
Outcomes Outcomes reported: exposure and surface contamination
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Confounding bias Unclear risk Risk of bias: no information
Comment: no information to judge
whether the confounding factors were bal-
anced across groups
Selection bias Low risk Risk of bias: low
Comment: the research was performed in
the same centre
Bias in classification of interventions Low risk Risk of bias: low
Comment: the intervention and control
were well defined
Bias due to deviations from intended inter-
ventions
High risk Risk of bias: serious
Comment: the pharmacists/technicians/
nurses received received training prior to
use of CSTD. No such training was prob-
ably provided in the control group
Bias due to missing data Low risk Risk of bias: low
Comment: all samples were included in the
analysis
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Wick 2003 (Continued)
Bias in measurement of outcomes High risk Risk of bias: serious
Comment: the outcome assessors do not
seem to be blinded to the groups
Bias in selection of the reported result Low risk Risk of bias: low
Comment: all results seem to be reported
Yoshida 2009
Methods Uncontrolled before-after cohort study; cluster study
Participants Country: Japan
Number of clusters: 2
Number excluded: 0 (0%)
Number included: 2
Chemotherapy agents tested for contamination: cyclophosphamide
Professional role: pharmacist
Size of the hospitals/wards: not stated
Interventions Group 1: CSTD + standard care (PhaSeal) (N = 1)
Group 2: standard care (Biological safety cabinet and personal protection equipment)
(N = 1)
Outcomes Outcomes reported: exposure and surface contamination
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Confounding bias Unclear risk Risk of bias: no information
Comment: no information to judge
whether the confounding factors were bal-
anced across groups
Selection bias Low risk Risk of bias: low
Comment: the research was performed in
the same centre
Bias in classification of interventions Low risk Risk of bias: low
Comment: the intervention and control
were well defined
Bias due to deviations from intended inter-
ventions
High risk Risk of bias: serious
Comment: the pharmacists received re-
ceived training prior to use of CSTD. No
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Yoshida 2009 (Continued)
such training was probably provided in the
control group
Bias due to missing data Low risk Risk of bias: low
Comment: all samples were included in the
analysis
Bias in measurement of outcomes High risk Risk of bias: serious
Comment: the outcome assessors do not
seem to be blinded to the groups
Bias in selection of the reported result Low risk Risk of bias: low
Comment: all results seem to be reported
Yoshida 2011
Methods Cross-sectional study; cluster study
Participants Country: Japan
Number of clusters: 5
Number excluded: not stated
Number included: 5
Chemotherapy agents tested for contamination: cyclophosphamide; 5-fluorouracil, gem-
citabine, and platinum-containing drugs
Professional role: pharmacist
Size of the hospitals/wards: not stated
Interventions Group 1: CSTD + standard care (not stated) (N = 3)
Group 2: standard care (variable) (N = 2)
Outcomes None of the outcomes of interest were reported.
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Confounding bias Unclear risk Risk of bias: no information
Comment: no information to judge whether the
confounding factors were balanced across groups
Selection bias Unclear risk Risk of bias: moderate
Comment: the participating centres were proba-
bly selected based on their pharmacological prac-
tices
67Closed-system drug-transfer devices plus safe handling of hazardous drugs versus safe handling alone for reducing exposure to infusional
hazardous drugs in healthcare staff (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Yoshida 2011 (Continued)
Bias in classification of interventions Low risk Risk of bias: low
Comment: the intervention and control were well
defined
Bias due to deviations from intended inter-
ventions
Unclear risk Risk of bias: no information
Comment: no information to judge whether the
co-interventions were similar across the groups
Bias due to missing data Low risk Risk of bias: low
Comment: all samples were included in the anal-
ysis
Bias in measurement of outcomes High risk Risk of bias: serious
Comment: the outcome assessors do not seem to
be blinded to the groups
Bias in selection of the reported result High risk Risk of bias: serious
Comment: the authors have not reported the re-
sults in a format from which inferences could be
made
CSTD: closed-system transfer device.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Amos 2012 Comparison of different CSTDs
Blazawski 2013 Simulation study
Chantry 2015 Simulation study
Clark 2013 Not a study comparing CSTD versus standard care
Connor 2010 Not a study comparing CSTD versus standard care
Contractor 2015 Not a study comparing CSTD versus standard care
Cox 2017 Not a study comparing CSTD versus standard care
De Ausen 2013 Simulation study
68Closed-system drug-transfer devices plus safe handling of hazardous drugs versus safe handling alone for reducing exposure to infusional
hazardous drugs in healthcare staff (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
De Prijck 2008 Simulation study
DeFreitas 2012 Simulation study
Enciso-Zarate 2016 Not a study comparing CSTD versus standard care
Favier 2012 Simulation study
Fernandez 2013 Simulation study
Garrigue 2016 Simulation study
Gebel 2015 Simulation study
Gilles 2009 Not a study comparing CSTD versus standard care
Gomez-Alvarez 2016 Simulation study
Gonzalez-Haba Pena 2016 Simulation study
Hama 2011 Simulation study
Hong 2017 Not a study comparing CSTD versus standard care
Hospital Employee Health 2005 Not a primary research study
Hospital Infection Control 2005 Not a primary research study
Idell 2009 Not a study comparing CSTD versus standard care
Ikeno 2014 Simulation study
Jorgenson 2008 Simulation study
Kopp 2013 Not a study comparing CSTD versus standard care
Kunneva 2016 Not a primary research study
Kurihara 2017 Not a study comparing CSTD versus standard care
Laws 2016 Not a primary research study
Le Garlantezec 2011 Simulation study
Ledford 2010 Comparison of different CSTDs
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(Continued)
Lennan 2017 Not a primary research study
Lin 2017 Simulation study
McDiarmid 2010 Intermittent use of CSTD (not possible to determine whether the outcomes are for CSTD or
standard care)
McMichael 2011 Simulation study
Meade 2015 Not a primary research study
Nishigaki 2010 Simulation study
Nygren 2005 Not a study comparing CSTD versus standard care
Nygren 2008 Simulation study
Nyman 2007 Not a study comparing CSTD versus standard care
Odraska 2013 Not a study comparing CSTD versus standard care
Oncology Nurse Advisor 2017 Not a primary research study
Perlo 2015 Simulation study
Queruau Lamerie 2012 Simulation study
Rupp 2017 Simulation study
Sanchez-Rubio Ferrandez 2012 Simulation study
Sanchez-Rubio Ferrandez 2012a Simulation study
Sato 2010 Simulation study
Sessink 1999 Not a study comparing CSTD versus standard care
Simon 2010 Simulation study
Smith 2014 Simulation study
Talsmar 2015 Not a primary research study
Thomas Carey 2011 Simulation study
Tyler 2017 Not a study comparing CSTD versus standard care
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Vyas 2016 Simulation study
Yoshida 2013 Not a study comparing CSTD versus standard care
CSTD: closed-system transfer device.
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D A T A A N D A N A L Y S E S
Comparison 1. Closed-system transfer device plus safe handling versus safe handling alone




participants Statistical method Effect size
1 Urine tests for exposure 4 Risk Ratio (Random, 95% CI) Subtotals only
1.1 Cyclophoshamide 2 Risk Ratio (Random, 95% CI) 0.83 [0.46, 1.52]
1.2 Cyclophosphamide or
ifosfamide
1 Risk Ratio (Random, 95% CI) 0.09 [0.00, 2.79]
1.3 Cyclophosphamide,
ifosfamide, or gemcitabine
1 Risk Ratio (Random, 95% CI) 0.0 [0.0, 0.0]
2 Proportion of surfaces
contaminated
14 Risk Ratio (Random, 95% CI) Subtotals only
2.1 Cyclophosphamide
(pharmacy areas)
13 Risk Ratio (Random, 95% CI) 0.89 [0.78, 1.01]
2.2 Ifosfamide (pharmacy
areas)
9 Risk Ratio (Random, 95% CI) 0.94 [0.74, 1.19]
2.3 Methotrexate (pharmacy
areas)
6 Risk Ratio (Random, 95% CI) 0.84 [0.58, 1.22]
2.4 5-fluorouracil (pharmacy
areas)
3 Risk Ratio (Random, 95% CI) 0.65 [0.43, 0.97]
2.5 Cytarabine (pharmacy
areas)
2 Risk Ratio (Random, 95% CI) 0.72 [0.18, 2.86]
2.6 Gemcitabine (pharmacy
areas)
2 Risk Ratio (Random, 95% CI) 0.96 [0.60, 1.54]
2.7 Irinotecan (pharmacy
areas)
1 Risk Ratio (Random, 95% CI) 0.36 [0.10, 1.33]
2.8 Docetaxel (pharmacy
areas)
1 Risk Ratio (Random, 95% CI) 0.0 [0.0, 0.0]
2.9 Paclitaxel (pharmacy
areas)
1 Risk Ratio (Random, 95% CI) 0.57 [0.04, 9.06]
2.10 Vinorelbine (pharmacy
areas)
1 Risk Ratio (Random, 95% CI) 1.72 [0.16, 18.73]
2.11 Ganciclovir (pharmacy
areas)
1 Risk Ratio (Random, 95% CI) 0.01 [0.00, 27.11]
2.12 Multiple drugs
(pharmacy areas)
1 Risk Ratio (Random, 95% CI) 0.87 [0.43, 1.77]
2.13 Cyclophosphamide
(patient-care areas)
5 Risk Ratio (Random, 95% CI) 1.01 [0.86, 1.18]
2.14 Ifosfamide (patient-care
areas)
5 Risk Ratio (Random, 95% CI) 1.44 [0.91, 2.28]
2.15 Methotrexate (patient-
care areas)
5 Risk Ratio (Random, 95% CI) 1.00 [0.55, 1.85]
2.16 5-fluorouracil (patient-
care areas)
1 Risk Ratio (Random, 95% CI) 1.09 [0.53, 2.23]
2.17 Cytarabine (patient-care
areas)
1 Risk Ratio (Random, 95% CI) 0.59 [0.01, 24.53]
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2.18 Gemcitabine (patient-
care areas)
1 Risk Ratio (Random, 95% CI) 1.13 [0.55, 2.33]
2.19 Irinotecan (patient-care
areas)
1 Risk Ratio (Random, 95% CI) 0.44 [0.03, 6.15]
2.20 Docetaxel (patient-care
areas)
1 Risk Ratio (Random, 95% CI) 0.59 [0.01, 24.53]
2.21 Paclitaxel (patient-care
areas)
1 Risk Ratio (Random, 95% CI) 0.59 [0.01, 24.53]
2.22 Vinorelbine (patient-care
areas)
1 Risk Ratio (Random, 95% CI) 0.0 [0.0, 0.0]
2.23 Multiple drugs (patient-
care areas)
1 Risk Ratio (Random, 95% CI) 2.38 [0.69, 8.23]
3 Quantity of surface
contamination (pg/cm²)
8 Mean Difference (Random, 95% CI) Subtotals only
3.1 Cyclophosphamide
(pharmacy areas)




6 Mean Difference (Random, 95% CI) -0.32 [-6.58, 5.94]
3.3 Methotrexate (pharmacy
areas)
6 Mean Difference (Random, 95% CI) -3.09 [-13.80, 7.61]
3.4 5-fluorouracil (pharmacy
areas)




1 Mean Difference (Random, 95% CI) -0.6 [-15.67, 14.47]
3.6 Gemcitabine (pharmacy
areas)












5 Mean Difference (Random, 95% CI) 3.59 [-3.45, 10.63]
3.10 Methotrexate (patient-
care areas)
5 Mean Difference (Random, 95% CI) 0.10 [-0.57, 0.78]
3.11 5-fluorouracil (patient-
care areas)




1 Mean Difference (Random, 95% CI) -0.20 [-0.79, 0.39]
3.13 Gemcitabine (patient-
care areas)
1 Mean Difference (Random, 95% CI) 0.47 [-1.77, 2.71]
3.14 Irinotecan (patient-care
areas)
1 Mean Difference (Random, 95% CI) -0.05 [-0.15, 0.05]
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Comparison 2. Subgroup analysis (based on study design and device)




participants Statistical method Effect size
1 Urine tests for exposure (PhaSeal
only)
3 Risk Ratio (Random, 95% CI) Subtotals only
1.1 Cyclophoshamide 2 Risk Ratio (Random, 95% CI) 0.83 [0.46, 1.52]
1.2 Cyclophosphamide or
ifosfamide
1 Risk Ratio (Random, 95% CI) 0.09 [0.00, 2.79]
2 Proportion of surfaces
contaminated with
cyclophosphamide in pharmacy
areas: stratified by study design
13 Risk Ratio (Random, 95% CI) 0.89 [0.78, 1.01]
2.1 Uncontrolled before-after
studies
7 Risk Ratio (Random, 95% CI) 0.87 [0.76, 0.99]
2.2 Cross-sectional studies 6 Risk Ratio (Random, 95% CI) 0.92 [0.72, 1.19]
3 Proportion of surfaces
contaminated with ifosfamide
in pharmacy areas: stratified by
study design
9 Risk Ratio (Random, 95% CI) 0.94 [0.74, 1.19]
3.1 Uncontrolled before-after
studies
3 Risk Ratio (Random, 95% CI) 0.85 [0.64, 1.14]
3.2 Cross-sectional studies 6 Risk Ratio (Random, 95% CI) 1.00 [0.65, 1.53]
4 Proportion of surfaces
contaminated with
methotrexate in pharmacy
areas: stratified by study design
6 Risk Ratio (Random, 95% CI) 0.84 [0.58, 1.22]
4.1 Uncontrolled before-after
studies
1 Risk Ratio (Random, 95% CI) 3.00 [0.01, 777.04]
4.2 Cross-sectional studies 5 Risk Ratio (Random, 95% CI) 0.83 [0.57, 1.22]
5 Proportion of surfaces
contaminated with
5-fluorouracil in pharmacy
areas: stratified by study design
3 Risk Ratio (Random, 95% CI) 0.65 [0.43, 0.97]
5.1 Uncontrolled before-after
studies
1 Risk Ratio (Random, 95% CI) 0.61 [0.36, 1.03]
5.2 Cross-sectional studies 2 Risk Ratio (Random, 95% CI) 0.71 [0.38, 1.34]
6 Proportion of surfaces
contaminated (PhaSeal only)
8 Risk Ratio (Random, 95% CI) Subtotals only
6.1 Cyclophosphamide
(pharmacy areas)
8 Risk Ratio (Random, 95% CI) 0.88 [0.78, 0.99]
6.2 Ifosfamide (pharmacy
areas)
4 Risk Ratio (Random, 95% CI) 0.84 [0.63, 1.11]
6.3 Methotrexate (pharmacy
areas)
1 Risk Ratio (Random, 95% CI) 3.00 [0.01, 777.04]
6.4 5-fluorouracil (pharmacy
areas)
2 Risk Ratio (Random, 95% CI) 0.61 [0.36, 1.02]
6.5 Cytarabine (pharmacy
areas)
1 Risk Ratio (Random, 95% CI) 0.35 [0.08, 1.58]
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6.6 Gemcitabine (pharmacy
areas)
1 Risk Ratio (Random, 95% CI) 0.88 [0.33, 2.33]
6.7 Ganciclovir (pharmacy
areas)
1 Risk Ratio (Random, 95% CI) 0.01 [0.00, 27.11]
7 Quantity of surface
contamination with
cyclophosphamide in pharmacy
areas (pg/cm²): stratified by
study design




2 Mean Difference (Random, 95% CI) -255.35 [-1144.66,
633.96]
7.2 Cross-sectional studies 5 Mean Difference (Random, 95% CI) -49.02 [-83.82, -14.
22]
8 Quantity of surface
contamination with ifosfamide
in pharmacy areas (pg/cm²):
stratified by study design
6 Mean Difference (Random, 95% CI) -0.32 [-6.58, 5.94]
8.1 Uncontrolled before-after
studies
1 Mean Difference (Random, 95% CI) -2.59 [-26.75, 21.
57]
8.2 Cross-sectional studies 5 Mean Difference (Random, 95% CI) -0.78 [-8.58, 7.03]
9 Quantity of surface
contamination with
methotrexate in pharmacy areas
(pg/cm²): stratified by study
design
6 Mean Difference (Random, 95% CI) -3.09 [-13.80, 7.61]
9.1 Uncontrolled before-after
studies
1 Mean Difference (Random, 95% CI) 10.34 [-34.01, 54.
69]
9.2 Cross-sectional studies 5 Mean Difference (Random, 95% CI) -3.92 [-14.96, 7.11]
10 Quantity of surface
contamination (pg/cm²):
stratified by devices
3 Mean Difference (Random, 95% CI) Subtotals only
10.1 Cyclophosphamide
(pharmacy areas; PhaSeal)












1 Mean Difference (Random, 95% CI) 14300.0 [-47951.46,
76551.46]
Comparison 3. Sensitivity analysis




participants Statistical method Effect size
1 Urine tests for exposure (ICC =
0.05)
4 Risk Ratio (Random, 95% CI) Subtotals only
1.1 Cyclophoshamide 2 Risk Ratio (Random, 95% CI) 0.82 [0.44, 1.52]
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1.2 Cyclophosphamide or
ifosfamide
1 Risk Ratio (Random, 95% CI) 0.09 [0.00, 1.99]
1.3 Cyclophosphamide,
ifosfamide, or gemcitabine
1 Risk Ratio (Random, 95% CI) 0.0 [0.0, 0.0]
2 Urine tests for exposure (ICC =
0.01)
4 Risk Ratio (Random, 95% CI) Subtotals only
2.1 Cyclophoshamide 2 Risk Ratio (Random, 95% CI) 0.81 [0.43, 1.51]
2.2 Cyclophosphamide or
ifosfamide
1 Risk Ratio (Random, 95% CI) 0.09 [0.01, 1.48]
2.3 Cyclophosphamide,
ifosfamide, or gemcitabine
1 Risk Ratio (Random, 95% CI) 0.0 [0.0, 0.0]
3 Urine tests for exposure (ICC =
0.00)
4 Risk Ratio (Random, 95% CI) Subtotals only
3.1 Cyclophoshamide 2 Risk Ratio (Random, 95% CI) 0.81 [0.43, 1.51]
3.2 Cyclophosphamide or
ifosfamide
1 Risk Ratio (Random, 95% CI) 0.09 [0.01, 1.36]
3.3 Cyclophosphamide,
ifosfamide, or gemcitabine
1 Risk Ratio (Random, 95% CI) 0.0 [0.0, 0.0]
4 Proportion of surfaces
contaminated (ICC = 0.05)
14 Risk Ratio (Random, 95% CI) Subtotals only
4.1 Cyclophosphamide
(pharmacy areas)
13 Risk Ratio (Random, 95% CI) 0.87 [0.76, 0.99]
4.2 Ifosfamide (pharmacy
areas)
9 Risk Ratio (Random, 95% CI) 0.94 [0.73, 1.23]
4.3 Methotrexate (pharmacy
areas)
6 Risk Ratio (Random, 95% CI) 0.84 [0.60, 1.19]
4.4 5-fluorouracil (pharmacy
areas)
3 Risk Ratio (Random, 95% CI) 0.65 [0.45, 0.94]
4.5 Cytarabine (pharmacy
areas)
2 Risk Ratio (Random, 95% CI) 0.68 [0.17, 2.67]
4.6 Gemcitabine (pharmacy
areas)
2 Risk Ratio (Random, 95% CI) 0.95 [0.64, 1.43]
4.7 Irinotecan (pharmacy
areas)
1 Risk Ratio (Random, 95% CI) 0.36 [0.11, 1.19]
4.8 Docetaxel (pharmacy
areas)
1 Risk Ratio (Random, 95% CI) 0.0 [0.0, 0.0]
4.9 Paclitaxel (pharmacy
areas)
1 Risk Ratio (Random, 95% CI) 0.57 [0.05, 7.13]
4.10 Vinorelbine (pharmacy
areas)
1 Risk Ratio (Random, 95% CI) 1.72 [0.20, 15.25]
4.11 Ganciclovir (pharmacy
areas)
1 Risk Ratio (Random, 95% CI) 0.01 [0.00, 3.43]
4.12 Multiple drugs
(pharmacy areas)
1 Risk Ratio (Random, 95% CI) 0.87 [0.49, 1.53]
4.13 Cyclophosphamide
(patient-care areas)
5 Risk Ratio (Random, 95% CI) 1.00 [0.86, 1.17]
4.14 Ifosfamide (patient-care
areas)
5 Risk Ratio (Random, 95% CI) 1.46 [0.91, 2.34]
4.15 Methotrexate (patient-
care areas)
5 Risk Ratio (Random, 95% CI) 1.01 [0.57, 1.76]
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4.16 5-fluorouracil (patient-
care areas)
1 Risk Ratio (Random, 95% CI) 1.09 [0.57, 2.10]
4.17 Cytarabine (patient-care
areas)
1 Risk Ratio (Random, 95% CI) 0.59 [0.02, 18.10]
4.18 Gemcitabine (patient-
care areas)
1 Risk Ratio (Random, 95% CI) 1.13 [0.58, 2.20]
4.19 Irinotecan (patient-care
areas)
1 Risk Ratio (Random, 95% CI) 0.44 [0.04, 4.97]
4.20 Docetaxel (patient-care
areas)
1 Risk Ratio (Random, 95% CI) 0.59 [0.02, 18.10]
4.21 Paclitaxel (patient-care
areas)
1 Risk Ratio (Random, 95% CI) 0.59 [0.02, 18.10]
4.22 Vinorelbine (patient-care
areas)
1 Risk Ratio (Random, 95% CI) 0.0 [0.0, 0.0]
4.23 Multiple drugs (patient-
care areas)
1 Risk Ratio (Random, 95% CI) 2.38 [0.79, 7.17]
5 Proportion of surfaces
contaminated (ICC = 0.01)
14 Risk Ratio (Random, 95% CI) Subtotals only
5.1 Cyclophosphamide
(pharmacy areas)
13 Risk Ratio (Random, 95% CI) 0.83 [0.73, 0.96]
5.2 Ifosfamide (pharmacy
areas)
9 Risk Ratio (Random, 95% CI) 0.89 [0.66, 1.21]
5.3 Methotrexate (pharmacy
areas)
6 Risk Ratio (Random, 95% CI) 0.85 [0.62, 1.16]
5.4 5-fluorouracil (pharmacy
areas)
3 Risk Ratio (Random, 95% CI) 0.65 [0.47, 0.90]
5.5 Cytarabine (pharmacy
areas)
2 Risk Ratio (Random, 95% CI) 0.64 [0.17, 2.51]
5.6 Gemcitabine (pharmacy
areas)
2 Risk Ratio (Random, 95% CI) 0.93 [0.69, 1.24]
5.7 Irinotecan (pharmacy
areas)
1 Risk Ratio (Random, 95% CI) 0.36 [0.12, 1.08]
5.8 Docetaxel (pharmacy
areas)
1 Risk Ratio (Random, 95% CI) 0.0 [0.0, 0.0]
5.9 Paclitaxel (pharmacy
areas)
1 Risk Ratio (Random, 95% CI) 0.57 [0.06, 5.79]
5.10 Vinorelbine (pharmacy
areas)
1 Risk Ratio (Random, 95% CI) 1.72 [0.23, 12.73]
5.11 Ganciclovir (pharmacy
areas)
1 Risk Ratio (Random, 95% CI) 0.01 [0.00, 0.27]
5.12 Multiple drugs
(pharmacy areas)
1 Risk Ratio (Random, 95% CI) 0.87 [0.57, 1.32]
5.13 Cyclophosphamide
(patient-care areas)
5 Risk Ratio (Random, 95% CI) 1.00 [0.85, 1.17]
5.14 Ifosfamide (patient-care
areas)
5 Risk Ratio (Random, 95% CI) 1.47 [0.91, 2.38]
5.15 Methotrexate (patient-
care areas)
5 Risk Ratio (Random, 95% CI) 1.01 [0.60, 1.69]
5.16 5-fluorouracil (patient-
care areas)
1 Risk Ratio (Random, 95% CI) 1.09 [0.59, 2.00]
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5.17 Cytarabine (patient-care
areas)
1 Risk Ratio (Random, 95% CI) 0.59 [0.02, 13.92]
5.18 Gemcitabine (patient-
care areas)
1 Risk Ratio (Random, 95% CI) 1.13 [0.61, 2.09]
5.19 Irinotecan (patient-care
areas)
1 Risk Ratio (Random, 95% CI) 0.44 [0.05, 4.13]
5.20 Docetaxel (patient-care
areas)
1 Risk Ratio (Random, 95% CI) 0.59 [0.02, 13.92]
5.21 Paclitaxel (patient-care
areas)
1 Risk Ratio (Random, 95% CI) 0.59 [0.02, 13.92]
5.22 Vinorelbine (patient-care
areas)
1 Risk Ratio (Random, 95% CI) 0.0 [0.0, 0.0]
5.23 Multiple drugs (patient-
care areas)
1 Risk Ratio (Random, 95% CI) 2.38 [0.89, 6.33]
6 Proportion of surfaces
contaminated (ICC = 0.00)
14 Risk Ratio (Random, 95% CI) Subtotals only
6.1 Cyclophosphamide
(pharmacy areas)
13 Risk Ratio (Random, 95% CI) 0.82 [0.72, 0.94]
6.2 Ifosfamide (pharmacy
areas)
9 Risk Ratio (Random, 95% CI) 0.85 [0.59, 1.21]
6.3 Methotrexate (pharmacy
areas)
6 Risk Ratio (Random, 95% CI) 0.86 [0.63, 1.16]
6.4 5-fluorouracil (pharmacy
areas)
3 Risk Ratio (Random, 95% CI) 0.65 [0.48, 0.88]
6.5 Cytarabine (pharmacy
areas)
2 Risk Ratio (Random, 95% CI) 0.64 [0.16, 2.46]
6.6 Gemcitabine (pharmacy
areas)
2 Risk Ratio (Random, 95% CI) 0.91 [0.73, 1.13]
6.7 Irinotecan (pharmacy
areas)
1 Risk Ratio (Random, 95% CI) 0.36 [0.13, 1.05]
6.8 Docetaxel (pharmacy
areas)
1 Risk Ratio (Random, 95% CI) 0.0 [0.0, 0.0]
6.9 Paclitaxel (pharmacy
areas)
1 Risk Ratio (Random, 95% CI) 0.57 [0.06, 5.48]
6.10 Vinorelbine (pharmacy
areas)
1 Risk Ratio (Random, 95% CI) 1.72 [0.24, 12.15]
6.11 Ganciclovir (pharmacy
areas)
1 Risk Ratio (Random, 95% CI) 0.01 [0.00, 0.09]
6.12 Multiple drugs
(pharmacy areas)
1 Risk Ratio (Random, 95% CI) 0.87 [0.60, 1.26]
6.13 Cyclophosphamide
(patient-care areas)
5 Risk Ratio (Random, 95% CI) 1.00 [0.85, 1.17]
6.14 Ifosfamide (patient-care
areas)
5 Risk Ratio (Random, 95% CI) 1.48 [0.91, 2.38]
6.15 Methotrexate (patient-
care areas)
5 Risk Ratio (Random, 95% CI) 1.01 [0.61, 1.67]
6.16 5-fluorouracil (patient-
care areas)
1 Risk Ratio (Random, 95% CI) 1.09 [0.60, 1.97]
6.17 Cytarabine (patient-care
areas)
1 Risk Ratio (Random, 95% CI) 0.59 [0.02, 14.36]
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6.18 Gemcitabine (patient-
care areas)
1 Risk Ratio (Random, 95% CI) 1.13 [0.62, 2.06]
6.19 Irinotecan (patient-care
areas)
1 Risk Ratio (Random, 95% CI) 0.44 [0.05, 3.93]
6.20 Docetaxel (patient-care
areas)
1 Risk Ratio (Random, 95% CI) 0.59 [0.02, 14.36]
6.21 Paclitaxel (patient-care
areas)
1 Risk Ratio (Random, 95% CI) 0.59 [0.02, 14.36]
6.22 Vinorelbine (patient-care
areas)
1 Risk Ratio (Random, 95% CI) 0.0 [0.0, 0.0]
6.23 Multiple drugs (patient-
care areas)
1 Risk Ratio (Random, 95% CI) 2.38 [0.92, 6.12]
7 Quantity of surface
contamination (pg/cm²) (ICC
= 0.05)
8 Mean Difference (Random, 95% CI) Subtotals only
7.1 Cyclophosphamide
(pharmacy areas)




6 Mean Difference (Random, 95% CI) -0.95 [-7.63, 5.72]
7.3 Methotrexate (pharmacy
areas)
6 Mean Difference (Random, 95% CI) -2.78 [-12.45, 6.89]
7.4 5-fluorouracil (pharmacy
areas)




1 Mean Difference (Random, 95% CI) -0.6 [-14.37, 13.17]
7.6 Gemcitabine (pharmacy
areas)












5 Mean Difference (Random, 95% CI) 3.59 [-2.88, 10.07]
7.10 Methotrexate (patient-
care areas)
5 Mean Difference (Random, 95% CI) 0.10 [-0.51, 0.72]
7.11 5-fluorouracil (patient-
care areas)




1 Mean Difference (Random, 95% CI) -0.20 [-0.74, 0.34]
7.13 Gemcitabine (patient-
care areas)
1 Mean Difference (Random, 95% CI) 0.47 [-1.59, 2.53]
7.14 Irinotecan (patient-care
areas)
1 Mean Difference (Random, 95% CI) -0.05 [-0.14, 0.04]
8 Quantity of surface
contamination (pg/cm²) (ICC
= 0.01)
8 Mean Difference (Random, 95% CI) Subtotals only
8.1 Cyclophosphamide
(pharmacy areas)




6 Mean Difference (Random, 95% CI) -1.29 [-7.89, 5.32]
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8.3 Methotrexate (pharmacy
areas)
6 Mean Difference (Random, 95% CI) -1.93 [-10.50, 6.64]
8.4 5-fluorouracil (pharmacy
areas)




1 Mean Difference (Random, 95% CI) -0.6 [-13.23, 12.03]
8.6 Gemcitabine (pharmacy
areas)












5 Mean Difference (Random, 95% CI) 3.59 [-2.39, 9.58]
8.10 Methotrexate (patient-
care areas)
5 Mean Difference (Random, 95% CI) 0.06 [-0.81, 0.94]
8.11 5-fluorouracil (patient-
care areas)




1 Mean Difference (Random, 95% CI) -0.2 [-0.70, 0.30]
8.13 Gemcitabine (patient-
care areas)
1 Mean Difference (Random, 95% CI) 0.47 [-1.43, 2.37]
8.14 Irinotecan (patient-care
areas)
1 Mean Difference (Random, 95% CI) -0.05 [-0.13, 0.03]
9 Quantity of surface
contamination (pg/cm²) (ICC
= 0.00)
8 Mean Difference (Random, 95% CI) Subtotals only
9.1 Cyclophosphamide
(pharmacy areas)




6 Mean Difference (Random, 95% CI) -1.36 [-7.81, 5.09]
9.3 Methotrexate (pharmacy
areas)
6 Mean Difference (Random, 95% CI) -1.32 [-9.47, 6.84]
9.4 5-fluorouracil (pharmacy
areas)




1 Mean Difference (Random, 95% CI) -0.6 [-12.93, 11.73]
9.6 Gemcitabine (pharmacy
areas)












5 Mean Difference (Random, 95% CI) 3.60 [-2.27, 9.46]
9.10 Methotrexate (patient-
care areas)
5 Mean Difference (Random, 95% CI) 0.03 [-1.02, 1.08]
9.11 5-fluorouracil (patient-
care areas)




1 Mean Difference (Random, 95% CI) -0.2 [-0.69, 0.29]
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